Implantable medical device for deployment across the atrioventricular septum

- CARDIAC PACEMAKERS, INC.

An implantable medical device (IMD) may be configured for deployment at a patient's atrioventricular septum in order to sense and/or pace a patient's heart. The atrioventricular septum of the patient's heart may have an atrial facing side defining part of the right atrium of the patient's heart and a ventricle facing side defining part of the left ventricle of the patient's heart. The IMD may include a first component configured to be positioned at least in part in the right atrium of the patient's heart proximate the atrioventricular septum, and a second component configured to be positioned at least in part in the left ventricle.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/271,647 filed on Dec. 28, 2015, the disclosure of which is incorporated herein by reference.

TECHNICAL FIELD

The present disclosure generally relates to implantable medical devices, and more particularly, to implantable medical devices that are configured to be deployed across the atrioventricular septum.

BACKGROUND

Implantable medical devices are commonly used today to monitor a patient and/or deliver therapy to a patient. For example, implantable sensors are often used to monitor one or more physiological parameters of a patient, such as heart beats, heart sounds, ECG, respiration, etc. In some instances, pacing devices are used to treat patients suffering from various heart conditions that may result in a reduced ability of the heart to deliver sufficient amounts of blood to a patient's body. Such heart conditions may lead to slow, rapid, irregular, and/or inefficient heart contractions. To help alleviate some of these conditions, various medical devices (e.g., pacemakers, defibrillators, etc.) can be implanted in a patient's body. Such devices may monitor and in some cases provide electrical stimulation to the heart to help the heart operate in a more normal, efficient and/or safe manner. In some instances, it may be beneficial to sense and/or pace two or more chambers of the heart.

SUMMARY

This disclosure provides design, delivery and deployment method, and clinical usage alternatives for medical devices. An example implantable medical device (IMD) configured for deployment at a patient's atrioventricular septum in order to sense and/or pace a patient's heart is disclosed, the atrioventricular septum of the patient's heart having an atrial facing side defining part of the right atrium of the patient's heart and a ventricle facing side defining part of the left ventricle of the patient's heart. The IMD includes a first component that is configured to be positioned at least in part in the right atrium of the patient's heart proximate the atrioventricular septum once the IMD is implanted and that includes a housing, a power source disposed within the housing and circuitry disposed within the housing and operably coupled to the power source. The IMD includes a second component that is configured to be positioned at least in part in the left ventricle of the patient's heart once the IMD is implanted and that is mechanically coupled to the first component through a passage passing through the atrioventricular septum. The second component includes a housing and two or more electrodes for sensing and/or pacing the left ventricle of the patient's heart.

Alternatively or additionally to any of the embodiments above, the first component further includes two or more electrodes for sensing and/or pacing the right atrium of the patient's heart.

Alternatively or additionally to any of the embodiments above, the two or more electrodes of the second component are operably coupled to the circuitry of the first component.

Alternatively or additionally to any of the embodiments above, at least one of the two or more electrodes of the second component engage the ventricle facing side of the atrioventricular septum of the patient's heart once the IMD is implanted.

Alternatively or additionally to any of the embodiments above, at least one of the two or more electrodes of the first component engage the atrial facing side of the atrioventricular septum of the patient's heart once the IMD is implanted.

Alternatively or additionally to any of the embodiments above, the second component is configured to move from a contracted state to an expanded state, wherein during implantation of the IMD, the second component is configured to pass through the passage through the atrioventricular septum in the contracted state and then move to the expanded state once in the left ventricle of the patient's heart.

Alternatively or additionally to any of the embodiments above, wherein in the expanded state, the second component extends laterally beyond a lateral extent of the passage through the atrioventricular septum and engages the ventricle facing side of the atrioventricular septum of the patient's heart.

Alternatively or additionally to any of the embodiments above, the first component extends distally beyond a delivery catheter and engages the atrial facing side of the atrioventricular septum of the patient's heart once the IMD is implanted.

Alternatively or additionally to any of the embodiments above, the second component is configured to cut the passage through the atrioventricular septum while the IMD is implanted.

Alternatively or additionally to any of the embodiments above, the second component is mechanically coupled to the first component through the passage via a connecting member.

Alternatively or additionally to any of the embodiments above, the connecting member is part of the second component, and forms an interference fit with the first component.

Alternatively or additionally to any of the embodiments above, the connecting member is part of the first component, and forms an interference fit with the first component.

Alternatively or additionally to any of the embodiments above, the first component comprises a fixation element for securing the first component to the atrioventricular septum of the patient's heart.

Alternatively or additionally to any of the embodiments above, the second component comprises a fixation element for securing the second component to the atrioventricular septum of the patient's heart.

An implantable medical device (IMD) configured for deployment at a patient's atrioventricular septum is disclosed, the atrioventricular septum of the patient's heart having an atrial facing side defining part of the right atrium of the patient's heart and a ventricle facing side defining part of the left ventricle of the patient's heart. The IMD includes a body having a first end portion, a second end portion and a connecting portion connecting the first end portion to the second end portion. At least part of the first end portion may be configured to be positioned in the right atrium of the patient's heart proximate the atrioventricular septum once the IMD is implanted and at least part of the second end portion extends into the left ventricle of the patient's heart once the IMD is implanted. The connecting portion extends through a passage that passes through the atrioventricular septum and the second end portion extends laterally beyond a lateral extent of the connecting portion to engage the ventricle facing side of the atrioventricular septum of the patient's heart once the IMD is implanted.

Alternatively or additionally to any of the embodiments above, the second end portion includes two or more electrodes for sensing and/or pacing the left ventricle of the patient's heart, wherein at least one of the two or more electrodes of the second end portion engages the ventricle facing side of the atrioventricular septum of the patient's heart.

Alternatively or additionally to any of the embodiments above, the first end portion includes two or more electrodes for sensing and/or pacing the right atrium of the patient's heart, wherein at least one of the two or more electrodes of the first end portion engages the atrial facing side of the atrioventricular septum of the patient's heart.

Alternatively or additionally to any of the embodiments above, at least part of the second end portion is configured to move from a contracted state to an expanded state.

A method of deploying a leadless pacing and sensing assembly proximate a patient's atrioventricular septum is disclosed, the leadless pacing and sensing assembly including a right atrial leadless cardiac pacemaker (LCP) and a left ventricular leadless cardiac pacemaker (LCP). The method includes advancing a delivery catheter through the patient's vasculature until a distal end of the delivery catheter is proximate an atrial side of the atrioventricular septum, the right atrial LCP disposed within a distal region of the delivery catheter. A deployment device is advanced past the right atrial LCP and through the atrioventricular septum, the left ventricular LCP secured to the deployment device such that the left ventricular LCP passes past the right atrial LCP and is disposed proximate a ventricular side of the atrioventricular septum. The left ventricular LCP is secured to the right atrial LCP and the deployment device is withdrawn.

Alternatively or additionally to any of the embodiments above, the method further comprises withdrawing the delivery catheter.

The above summary is not intended to describe each embodiment or every implementation of the present disclosure. Advantages and attainments, together with a more complete understanding of the disclosure, will become apparent and appreciated by referring to the following description and claims taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

The disclosure may be more completely understood in consideration of the following description of various illustrative embodiments in connection with the accompanying drawings, in which:

FIG. 1 is a schematic view of an upper portion of a human heart, showing the atrioventricular septum;

FIG. 2 is a schematic view of a dual chamber leadless cardiac pacemaker (LCP) arrangement shown in a delivery vehicle;

FIG. 3 is a schematic end view of the right seed of the dual chamber LCP arrangement of FIG. 2;

FIG. 4 is a schematic view of a human heart, showing the dual chamber LCP arrangement of FIG. 2 during deployment;

FIG. 5 is a schematic view of another implantable medical device configured for deployment across the atrioventricular septum;

FIG. 6 is a schematic view of yet another illustrative implantable medical device configured for deployment across the atrioventricular septum;

FIG. 7 is a schematic view of an illustrative LCP configured for deployment within the right atrium;

FIG. 8 is a block diagram of another illustrative LCP;

FIG. 9 is a schematic view of an illustrative two-part LCP, prior to deployment;

FIG. 10 is a schematic view of the illustrative two-part LCP of FIG. 9, during deployment;

FIG. 11 is a schematic view of the illustrative two-part LCP, after deployment;

FIG. 12 is a schematic view of another illustrative two-part LCP;

FIG. 13 is a schematic view of yet another illustrative two-part LCP;

FIG. 14 is a schematic view of another illustrative two-part LCP; and

FIG. 15 is a flow diagram showing an illustrative implantation method.

While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the disclosure to the particular illustrative embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.

DESCRIPTION

The following description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The description and the drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the disclosure.

All numbers are herein assumed to be modified by the term “about”, unless the content clearly dictates otherwise. The recitation of numerical ranges by endpoints includes all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).

As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include the plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.

It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it is contemplated that the feature, structure, or characteristic may be applied to other embodiments whether or not explicitly described unless clearly stated to the contrary.

The present disclosure generally relates to implantable medical devices, and more particularly, to implantable medical devices that are configured to be deployed across the atrioventricular septum. More particularly, the present disclosure is directed at providing pacing and/or sensing from a position next to or within the atrioventricular septum. In order to call out particular features of the cardiac anatomy, FIG. 1 provides a general illustration of a typical human heart 10. The heart 10 includes a right atrium RA and a left atrium LA. The left atrium LA is fluidly coupled to the pulmonary artery PA. A tricuspid valve TV separates the right atrium RA from a right ventricle RV. A mitral valve MV separates the left atrium LA from a left ventricle LV. Because the tricuspid valve TV is disposed apical (closer to the apex) of the mitral valve MV, an atrioventricular (AV) septum 12 exists. An arrow 14 indicates a portion of the AV septum 12 that may be used to provide access to both the right atrium RA and the left ventricle LV. The AV septum 12 includes an atrial side 16 that faces the right atrium RA as well as a ventricle side 18 that faces the left ventricle LV.

It will be appreciated that by traversing the AV septum 12 at or near the position indicated by the arrow 14, which is above the tricuspid valve TV and below the mitral valve MV, the left ventricle LV is accessible from the right atrium RA. This area can be reached, for example, via a transvenous catheter passing through either the SVC (superior vena cava) or the IVC (inferior vena cava) and into the right atrium RA. It will be appreciated that by deploying a two-part or multi-part LCP within the AV septum 12, it is possible to reach the left ventricle LV without having to potentially interfere with the mitral valve MV.

FIG. 2 provides a schematic view of an illustrative LCP assembly 20 that includes, as labeled, a right seed 22 and a left seed 24. In some cases, as illustrated, the right seed 22 may be configured to remain at least partially in the right atrium RA, and the left seed 24 may be configured to extend at least partially into the left ventricle LV. In some cases, the left seed 24 may be configured to pass through the right seed 22 during deployment, but this is not required. In some cases, the left seed 24 may have a diameter that is 3 French (F) or less. The illustrative LCP assembly 20 is shown disposed within a delivery catheter 26 which, as noted, may reach the right atrium RA via the SVC or the IVC. Which route is preferred may be a matter of the cardiologist's preferences, or may be at least in part a function of anatomical idiosyncrasies of a particular patient.

In some cases, the left seed 24 may be secured to a deployment mechanism 28 that can be used to advance the left seed 24 axially. The left seed 24 and the deployment mechanism 28 may be deployed within a hypotube 30 that may be configured to extend through the atrioventricular septum 12 (FIG. 1). In some cases, the hypotube 30 may have a distal end 32 that is configured to form a passage through the AV septum 12. In some instances, the distal end 32 of the hypotube 30 may be configured to poke a hole through the AV septum 12 without removing tissue from the AV septum 12. As a result, the left seed 24 may be advanced through the AV septum 12, through the hole made by the distal end 32 of the hypotube 30.

Once deployed, the left seed 24 may be disposed at least partially on the ventricular side 18 of the AV septum 12, and the right seed 22 may be disposed at least partially on the atrial side 16 of the AV septum 12 (FIG. 1). In some cases, the left seed 24 may be mechanically coupled to the right seed 22 in order to help secure the left seed 24 and the right seed 22 in place on either side of the AV septum 12. In some cases, the left seed 24 and/or the right seed 22 may include an anticoagulant coating. While not illustrated, it will be appreciated that the left seed 24 may include two or more electrodes for pacing and/or sensing within the left ventricle LV. In some cases, the electrodes on the left seed 24 may be electrically coupled with control circuitry within the right seed 22. In some cases, there may be a wired connection between the right seed 22 and the left seed 24. In some instances, there may be a wireless connection between the right seed 22 and the left seed 24.

FIG. 3 is a schematic end view of the right seed 22 of the dual chamber LCP arrangement of FIG. 2. The illustrative right seed 22 includes a central lumen 34 extending through a body portion 36. While generically illustrated, it will be appreciated that the body portion 36 may include internal components which, for simplicity, are not illustrated here. These internal components, which will be described with respect to subsequent drawings, may include one or more of circuitry and a power supply. The central lumen 34 may be sized to accommodate the left seed 24 extended therethrough. In some cases, as illustrated, the central lumen 34 may include one or more electrodes 38 lining at least a portion of the central lumen 34 for making electrical contact with one or more corresponding electrodes (not shown) on an outer surface of the left seed 24.

In some cases, the central lumen 34 may also include one or more fixation elements (not explicitly shown) that are configured to engage with the left seed 24 and secure the left seed 24 to the right seed 22 once the left seed 24 has been deployed. The one or more fixation elements may, for example, extend to form a frictional engagement with the left seed 24. In some cases, the one or more fixation elements may be stent-like, and may expand to engage the left seed 24. In some instances, the one or more fixation elements may be formed of a shape memory material that can have a delivery shape that permits the left seed 24 to pass through the central lumen 34 of the right seed 22 and then revert to a “remembered” shape that engages the left seed 24 once the one or more fixation elements reach a particular temperature, for example. The one or more fixation elements could be formed from any of a variety of shape memory polymers or metals. In some cases, the one or more fixation elements may be formed of a nickel-titanium alloy such as Nitinol.

The right seed 22 includes, as illustrated, a first electrode 40 and a second electrode 42 that may be electrically coupled to internal circuitry within the right seed 22. While two electrodes 40, 42 are illustrated, it will be appreciated that the right seed 22 may include additional electrodes, depending on the desired pacing and/or sensing capabilities. In some cases, the first electrode 40 and the second electrode 42 may be disposed on the distal side of the right seed 22 such that both the first electrode 40 and the second electrode 42 may be in contact with the atrial side 16 of the AV septum 12 once implanted.

FIG. 4 provides an illustrative but non-limiting deployment example. As can be seen in FIG. 4, a delivery catheter 26 (FIG. 2) has been passed up through the IVC and into the right atrium RA. In some cases, the delivery catheter 26 may be configured to include a curved distal portion that may help direct the LCP assembly 20 into position proximate the AV septum 12. In some cases, the delivery catheter 26 may be guided into position via an interaction with a chamber wall within the right atrium RA. In some instances, the delivery catheter 26 may be a steerable catheter. While not illustrated, in some cases the delivery catheter 26 and/or the LCP assembly 20 may include radiopaque structures that are visible during imaging processes such as fluoroscopy and/or ultrasound in order to facilitate directing the delivery catheter 26 to an appropriate position proximate the AV septum 12.

FIG. 5 is a schematic view of another illustrative implantable medical device (IMD) 50 that is configured to be deployed across the AV septum 12 (FIG. 1). The illustrative IMD 50 includes a body 52 having a first end portion 54, a second end portion 56, and a connecting portion 58 that connects the first end portion 54 and the second end portion 56. In some instances, a length of the connection portion 58 may be varied in order to accommodate the cardiac anatomy of a particular patient, in order to provide better electrode contact and to optimize the electrical performance of the IMD 50. In some cases, at least part of the first end portion 54 may be configured to be positioned in the right atrium RA proximate the AV septum 12 once implanted. Likewise, at least part of the second end portion 56 may be configured to extend into the left ventricle LV once implanted. It will be appreciated that the body 52 is shown schematically in FIG. 5, including the first end portion 54 and the second end portion 56.

Once implanted, it will be appreciated that the connecting portion 58 will extend through a passage that passes across the AV septum 12. In some cases, the passage may be formed directly by the second end portion 56 being forced through the AV septum 12. In some instances, the passage may be formed by a separate needle, hypotube or other suitable device prior to inserting the second end portion 56. The second end portion 56 may extend laterally (e.g. lateral relative to the major axis of the connecting portion 58) beyond a lateral extent of the connecting portion 58 in order to engage the ventricle side 18 (FIG. 1) of the AV septum 12 once the IMD 50 is implanted. In some cases, at least part of the second end portion 56 may be configured to move from a contracted state, such as for delivery to the AV septum 12 and insertion through the AV septum 12, to an expanded state, such as for anchoring the second end portion 56 relative to the ventricle side 18 of the AV septum 12.

In some cases, as illustrated, the second end portion 56 may include electrodes for sensing and/or pacing the left ventricle LV. In some cases, the second end portion 56 may include a first electrode 60 and a second electrode 62 that are positioned on the second end portion 56 such that the first electrode 60 and the second electrode 62 are able to engage the ventricle side 18 of the AV septum 12. In some instances, the second end portion 56 may also include additional electrodes, but this is not required. In some cases, the first end portion 54 may include electrodes for sensing and/or pacing the right atrium RA. In some cases, the first end portion 54 may include a first electrode 64 and a second electrode 66 that are positioned on the first end portion 54 such that the first electrode 64 and the second electrode 66 are able to engage the atrial side 16 of the AV septum 12. In some instances, the first end portion 54 may also include additional electrodes, but this is not required.

FIG. 6 is a schematic view of another illustrative IMD 70 that is configured to be deployed across the AV septum 12 (FIG. 1) in order to sense and/or pace the heart. In some cases, as illustrated, the illustrative IMD 70 may include a first component 72 that is configured to be positioned at least in part in the right atrium RA proximate the AV septum 12 once the IMD 70 is implanted, and a second component 74 that is configured to be positioned at least in part in the left ventricle LV once the IMD 70 is implanted. In some cases, the first component 72 includes a housing 76 and a power supply 78 that is disposed within the housing 76. Circuitry 80 may be disposed within the housing 76 and may be operably coupled to the power source 78. In some cases, the power source 78 may be wirelessly rechargeable.

The second component 74 may be mechanically coupled to the first component 72 through a passage passing through the AV septum 12. In some cases, the second component 74 is mechanically coupled to the first component 72 via a connecting member 82. In some cases, the connecting member 82 may be part of the second component 74 and may form an interference fit with the first component 72. In some cases, the connecting member 82 may be part of the first component 72 and may form an interference fit with the second component 74. In some cases, the first component 72 includes a fixation element for securing the first component 72 to the AV septum 12. In some instances, the second component 74 includes a fixation element for securing the second component 74 to the AV septum 12. Subsequent drawings will provides examples of such fixation elements, which may include one or more of barbs, spikes, pins, staples, threads, screws, helix, tines, and/or the like.

In some cases, the second component 74 may include a housing 84. The housing 84 may be a cylindrical body, for example. In some cases, the housing 84 may instead have another shape, or may simply be several insulated wires coupled together and including electrodes that are electrically coupled to the insulated wires, for example. In some instances, the housing 84 could be umbrella-shaped, with electrodes disposed at the tips of wires that may be joined together in a web. A first electrode 86 and a second electrode 88 may be disposed on the housing 84 and may be positioned such that the first electrode 86 and the second electrode 88 may be able to sense and/or pace the left ventricle LV of the heart. In some cases, the first electrode 86 and the second electrode 88 are configured to engage the ventricle side 18 (FIG. 1) of the AV septum 12. In some instances, the second component 74 may also include additional electrodes, but this is not required. In some instances, the first electrode 86 and the second electrode 88 may be operably coupled to the circuitry 80 of the first component 72. In some cases, wiring leads 90 and 92 may lead from the first electrode 86 and the second electrode 88, respectively, to the circuitry 80 and may pass through or over the connecting member 82.

In some cases, the first component 72 may include electrodes for sensing and/or pacing the right atrium RA. As illustrated, the first component 72 includes a first electrode 94 and a second electrode 96. In some cases, at least one of the first electrode 94 and the second electrode 96 may be positioned to engage the atrial side 16 (FIG. 1) of the AV septum 12 once implanted. In some instances, the first component 72 may also include additional electrodes, but this is not required. In some cases, wiring leads 98 and 99 may lead from the first electrode 94 and the second electrode 96, respectively, to the circuitry 80.

In some instances, the second component 74 may be configured to move from a contracted state to an expanded state. In some cases, the second component 74 may pass through the passage formed in the AV septum 12 while in its contracted state and then move into its expanded state once the second component 74 has reached the left ventricle LV. In some cases, when in its expanded state, the second component 74 may extend laterally beyond a lateral extent of the passage through the AV septum 12 and may engage the ventricle side 18 (FIG. 1) of the AV septum 12. In some cases, the first component 72 may extend laterally beyond the lateral extent of the passage through the AV septum 12 and may engage the atrial side 16 of the AV septum 12 once the IMD 70 is implanted. In some cases, the second component 74 may be configured to cut or otherwise form the passage extending through the AV septum 12. In some instances, a separate device may be used to form the passage through the AV septum 12.

FIG. 7 is a schematic view of an illustrative LCP 100 configured for deployment within the right atrium. The LCP may be configured to sense physiological signals and parameters and deliver one or more types of electrical stimulation therapy to the atrial side 16 (FIG. 1) of the AV septum 12. Example electrical stimulation therapy may include anti-tachycardia pacing (ATP) therapy, cardiac resynchronization therapy (CRT), bradycardia therapy, various types of pacing therapy including rate responsive pacing therapy, and/or the like. The LCP 100 may be considered as an example of the right seed 22 of FIG. 2. The LCP 100 may be a compact device with all components housed within or directly on a housing 120 of the LCP 100. The illustrative LCP 100 may include a communication module 102, a pulse generator module 104, an electrical sensing module 106, a mechanical sensing module 108, a processing module 110, an energy storage module 112, and electrodes 114.

In some cases, as illustrated, the LCP 100 may include a passage 122 that passes through the LCP 100 from a first side 124 of the housing 120 to a second side 126 of the housing 120. In some cases, the passage 122 is configured to allow the left seed 24 (FIG. 2) to extend through the passage 122 during implantation of the left seed 24. In some instances, as noted with respect to FIG. 2, the passage 122 may include structure that is configured to enable electrical communication between the left seed 24 and the right seed 22. In some cases, the passage 122 may include structure to help anchor the left seed 24 to the right seed 22 after deployment. In some cases, the LCP 100 may be configured such that the first side 124 or the second side 126 of the housing 120 may be deployed along the atrial side 16 (FIG. 1) of the AV septum 12. While the passage 122 is schematically illustrated as extending through the LCP 100 at or near a midpoint of the LCP 100, it will be appreciated that in some cases the passage 122 may be located at or near one edge of the LCP 100. In some cases, the passage 122 may be defined by structure that is secured to an outer surface of the housing 120. For example, depending on the exact size and configuration of the left seed 24, the passage 122 may be formed of a cylindrical tube secured to the outside of the housing 120.

The electrodes 114 may be secured relative to the housing 120 but may be exposed to the tissue and/or blood surrounding the LCP 100. The electrodes 114 may generally conduct electrical signals to and from the LCP 100 and the surrounding tissue and/or blood. Such electrical signals can include communication pulses, electrical stimulation pulses, and intrinsic cardiac electrical signals. Intrinsic cardiac electrical signals may include electrical signals generated by the heart and may be represented by an electrocardiogram (ECG). The electrodes 114 can be made up of one or more biocompatible conductive materials such as various metals or alloys that are known to be safe for implantation within a human body. In some instances, the electrodes 114 may be generally disposed on either side of LCP 100 and may be in electrical communication with one or more of modules 102, 104, 106, 108, and 110. In examples where the electrodes 114 are secured directly to the housing 120, the electrodes 114 may have an insulative portion that electrically isolates the electrodes 114 from adjacent electrodes, the housing 120, and/or other portions of the LCP 100. Some or all of the electrodes 114 may be spaced from the housing 120 and connected to the housing 120 and/or other components of the LCP 100 through connecting wires or the like.

The electrodes 114 and/or 114′ may have any of a variety of sizes and/or shapes, and may be spaced at any suitable distance. For example, the electrodes 114 may have a diameter of one to five millimeters (mm). However, in other examples, the electrodes 114 and/or 114′ may have a diameter of one mm, two mm, three mm, or any other suitable diameter, dimension and shape. Example lengths for the electrodes 114 and/or 114′ include a length of one mm, three mm, five mm, or any other suitable length. Additionally, at least some of the electrodes 114 and/or 114′ may be spaced from one another by a distance of five mm, six mm, seven mm, or any other suitable distance. The electrodes 114 and/or 114′ of a single device may have different sizes with respect to each other, and the spacing of the electrodes on the device may or may not be uniform. In some cases, the electrode 114 may be a cathode with a smaller electrode surface area and the electrode 114′ may be an anode electrode with a larger electrode surface.

The communication module 102 may be electrically coupled to the electrodes 114 and/or 114′ and configured to deliver communication pulses to tissues of the patient for communicating with other devices such as sensors, programmers, other medical devices, and the like. Communication pulses, as used herein, may be any modulated signal that conveys information to another device, either by itself or in conjunction with one or more other modulated signals. In some examples, communication pulses are sub-threshold signals which convey information, but this is not required. Other devices that the communication module 102 may be configured to communicate with may be located either external or internal to the patient's body. The communication module 102 may additionally be configured to sense for communication pulses delivered by the other devices, which are located externally to the LCP 100. Irrespective of the location, the LCP 100 and the other devices may communicate with each other via the communication module 102 to accomplish one or more desired functions. Some example functions include storing communicated data, using communicated data for determining occurrences of arrhythmias, coordinating delivery of electrical stimulation therapy, and/or other functions.

The LCP 100 and the other devices may use the delivered communication pulses to communicate raw information, processed information, messages, and/or other data. Raw information may include information such as sensed electrical signals (e.g. a sensed ECG), signals gathered from coupled sensors, and the like. In some examples, the raw information may include signals that have been filtered using one or more signal processing techniques. Processed information may include any information that has been determined by the LCP 100. For example, processed information may include a determined heart rate, timings of determined heartbeats, timings of other determined events, determinations of threshold crossings, expirations of monitored time periods, and determined parameters such as activity parameters, blood-oxygen parameters, blood pressure parameters, heart sound parameters, and the like. Messages may include instructions directing another device to take action, notifications of imminent actions of the sending device, requests for reading from the receiving device or writing data to the receiving device. In some cases, the LCP 100 may communicate with an S-ICD (subcutaneous implantable cardioinverter).

In at least some examples, the communication module 102 (or the LCP 100) may further include switching circuitry to selectively connect one or more of the electrodes 114 and/or 114′ to the communication module 102 in order to select via which electrodes 114 and/or 114′ the communication module 102 delivers the communication pulses. Additionally, the communication module 102 may be configured to use one or more methods for communicating with other devices. For example, the communication module 102 may communicate via conducted signals, radiofrequency (RF) signals, optical signals, acoustic signals, inductive coupling, and/or any other signals or methods suitable for communication with an external device such as an S-ICD or a programmer.

The pulse generator module 104 of the LCP 100 may also be electrically connected to one or more of the electrodes 114 and/or 114′. The pulse generator module 104 may be configured to generate electrical stimulation pulses and deliver the electrical stimulation pulses to tissues of a patient via the electrodes 114 and/or 114′ electrodes in order to effectuate one or more electrical stimulation therapies. Electrical stimulation pulses as used herein are meant to encompass any electrical signals that may be delivered to tissue of a patient for purposes of treatment of any type of disease or abnormality. When used to treat heart diseases or abnormalities, the electrical stimulation pulses may generally be configured so as to capture the heart of the patient—cause the heart to contract in response to the delivered electrical stimulation pulse. In at least examples where the pulse generator 104 is configured to generate specific types of electrical stimulation pulses termed defibrillation/cardioversion pulses, the pulse generator module 104 may include one or more capacitor elements.

The pulse generator module 104 may include capability to modify the electrical stimulation pulses, such as by adjusting a pulse width or amplitude of the electrical stimulation pulses, in order to ensure that the delivered electrical stimulation pulses consistently capture the heart. The pulse generator module 104 may use energy stored in the energy storage module 112 to generate the electrical stimulation pulses. In at least some examples, the pulse generator module 104 (or the LCP 100) may further include switching circuitry to selectively connect one or more of the electrodes 114 and/or 114′ to the pulse generator module 104 in order to select via which electrodes 114 and/or 114′ the pulse generator 104 delivers the electrical stimulation pulses.

In some examples, the LCP 100 may include the electrical sensing module 106 and the mechanical sensing module 108. The electrical sensing module 106 may be configured to sense intrinsic cardiac electrical signals conducted from the electrodes 114 and/or 114′ to the electrical sensing module 106. For example, the electrical sensing module 106 may be electrically connected to one or more electrodes 114 and/or 114′ and the electrical sensing module 106 may be configured to receive cardiac electrical signals conducted through the electrodes 114 and/or 114′. In some examples, the cardiac electrical signals may represent local information from the chamber in which the LCP 100 is implanted. For instance, if the LCP 100 is implanted within the right atrium RA, cardiac electrical signals sensed by the LCP 100 through the electrodes 114 and/or 114′ may represent atrial cardiac electrical signals. The mechanical sensing module 108 may include, or be electrically connected to, various sensors, such as accelerometers, blood pressure sensors, heart sound sensors, blood-oxygen sensors, and/or other sensors which measure one or more physiological parameters of the heart and/or patient. The mechanical sensing module 108 may gather signals from the sensors indicative of the various physiological parameters. Both the electrical sensing module 106 and the mechanical sensing module 108 may be further connected to the processing module 110 and may provide signals representative of the sensed cardiac electrical signals and/or physiological signals to processing the module 110. Although described with respect to FIG. 7 as separate sensing modules, in some examples, the electrical sensing module 106 and the mechanical sensing module 108 may be combined into a single module.

The processing module 110 may be configured to control the operation of the LCP 100. For example, the processing module 110 may be configured to receive cardiac electrical signals from the electrical sensing module 106 and/or physiological signals from the mechanical sensing module 108. Based on the received signals, the processing module 110 may determine occurrences and types of arrhythmias. The processing module 110 may further receive information from the communication module 102. In some examples, the processing module 110 may additionally use such received information to determine occurrences and types of arrhythmias. However, in other examples, the LCP 100 may use the received information instead of the signals received from the electrical sensing module 106 and/or the mechanical sensing module 108—for instance if the received information is more accurate than the signals received from the electrical sensing module 106 and/or the mechanical sensing module 108 or if the electrical sensing module 106 and/or the mechanical sensing module 108 have been disabled or omitted from the LCP 100.

Based on any determined arrhythmias, the processing module 110 may then control the pulse generator module 104 to generate electrical stimulation pulses in accordance with one or more electrical stimulation therapies to treat the determined arrhythmias. For example, the processing module 110 may control the pulse generator module 104 to generate pacing pulses with varying parameters and in different sequences to effectuate one or more electrical stimulation therapies. In controlling the pulse generator module 104 to deliver bradycardia pacing therapy, the processing module 110 may control the pulse generator module 104 to deliver pacing pulses designed to capture the heart of the patient at a regular interval to prevent the heart of a patient from falling below a predetermined threshold. For ATP therapy, the processing module 110 may control the pulse generator module 104 to deliver pacing pulses at a rate faster than an intrinsic heart rate of a patient in attempt to force the heart to beat in response to the delivered pacing pulses rather than in response to intrinsic cardiac electrical signals. The processing module 110 may then control the pulse generator module 104 to reduce the rate of delivered pacing pulses down to a safe level. In CRT, the processing module 110 may control the pulse generator module 104 to deliver pacing pulses in coordination with another device (e.g. the left seed 24) to cause the heart to contract more efficiently. Additionally, in cases where the pulse generator module 104 is capable of generating defibrillation and/or cardioversion pulses for defibrillation/cardioversion therapy, the processing module 110 may control the pulse generator module 104 to generate such defibrillation and/or cardioversion pulses. In some examples, the LCO 100 may instead communicate with an S-ICD for defibrillation therapy. In other examples, the processing module 110 may control the pulse generator module 104 to generate electrical stimulation pulses to provide electrical stimulation therapies different than those described herein to treat one or more detected cardiac arrhythmias.

Aside from controlling the pulse generator module 104 to generate different types of electrical stimulation pulses and in different sequences, in some examples, the processing module 110 may also control the pulse generator module 104 to generate the various electrical stimulation pulses with varying pulse parameters. For example, each electrical stimulation pulse may have a pulse width and a pulse amplitude. The processing module 110 may control the pulse generator module 104 to generate the various electrical stimulation pulses with specific pulse widths and pulse amplitudes. For example, the processing module 110 may cause the pulse generator module 104 to adjust the pulse width and/or the pulse amplitude of electrical stimulation pulses if the electrical stimulation pulses are not effectively capturing the heart. Such control of the specific parameters of the various electrical stimulation pulses may ensure that the LCP 100 is able to provide effective delivery of electrical stimulation therapy.

In some examples, the processing module 110 may further control the communication module 102 to send information to other devices. For example, the processing module 110 may control the communication module 102 to generate one or more communication pulses for communicating with other devices of a system of devices. For instance, the processing module 110 may control the communication module 102 to generate communication pulses in particular sequences, where the specific sequences convey different data to other devices. The communication module 102 may also conduct any received communication signals to the processing module 110 for potential action by the processing module 110.

In further examples, the processing module 110 may additionally control switching circuitry by which the communication module 102 and the pulse generator module 104 deliver communication pulses and electrical stimulation pulses to tissue of the patient. As described above, both the communication module 102 and the pulse generator module 104 may include circuitry for connecting one or more electrodes 114 and/114′ to the communication module 102 and the pulse generator module 104 so those modules may deliver the communication pulses and electrical stimulation pulses to tissue of the patient. The specific combination of one or more electrodes by which the communication module 102 and the pulse generator module 104 deliver communication pulses and electrical stimulation pulses influence the reception of communication pulses and/or the effectiveness of electrical stimulation pulses. Although it was described that each of the communication module 102 and the pulse generator module 104 may include switching circuitry, in some examples the LCP 100 may have a single switching module connected to all of the communication module 102, the pulse generator module 104, and the electrodes 114 and/or 114′. In such examples, the processing module 110 may control the single switching module to connect the modules 102/104 and the electrodes 114/114′.

In still additional examples, the processing module 110 may control the pulse generator module 104 to generate the communication pulses for communicating with external devices. In such examples, the communication module 102 may not include the capability to generate communication pulses. In some even additional examples, the electrical sensing module 106 may further include the capability to sense communication pulses. In such examples, the electrical sensing module 106 may communicate any received communication pulses to the processing module 110. In such examples, the LCP 100 may not include the communication module 102, as the functions of the communication module 102 are subsumed within the pulse generator module 104 and the electrical sensing module 106. However, in such examples, the LCP 100 may not be able to simultaneously generate both communication pulses and electrical stimulation pulses.

In some examples, the processing module 110 may include a pre-programmed chip, such as a very-large-scale integration (VLSI) chip or an application specific integrated circuit (ASIC). In such embodiments, the chip may be pre-programmed with control logic in order to control the operation of the LCP 100. By using a pre-programmed chip, the processing module 110 may use less power than other programmable circuits while able to maintain basic functionality, thereby increasing the battery life of the LCP 100. In other examples, the processing module 110 may include a programmable microprocessor or the like. Such a programmable microprocessor may allow a user to adjust the control logic of the LCP 100 after manufacture, thereby allowing for greater flexibility of the LCP 100 than when using a pre-programmed chip.

The processing module 110, in additional examples, may further include a memory circuit and the processing module 110 may store information on and read information from the memory circuit. In other examples, the LCP 100 may include a separate memory circuit (not shown) that is in communication with the processing module 110, such that the processing module 110 may read and write information to and from the separate memory circuit. The memory circuit, whether part of the processing module 110 or separate from the processing module 110 may have address lengths of, for example, eight bits. However, in other examples, the memory circuit may have address lengths of sixteen, thirty-two, or sixty-four bits, or any other bit length that is suitable. Additionally, the memory circuit may be volatile memory, non-volatile memory, or a combination of both volatile memory and non-volatile memory.

The energy storage module 112 may provide a power source to the LCP 100 for its operations. In some examples, the energy storage module 112 may be a non-rechargeable lithium-based battery. In other examples, the non-rechargeable battery may be made from other suitable materials known in the art. Because the LCP 100 is an implantable device, access to the LCP 100 may be limited. In such circumstances, it is necessary to have sufficient energy capacity to deliver therapy over an extended period of treatment such as days, weeks, months, or years. In some examples, the energy storage module 112 may a rechargeable battery in order to facilitate increasing the useable lifespan of the LCP 100. In still other examples, the energy storage module 112 may be other types of energy storage devices such as capacitors.

FIG. 8 is a block diagram of another illustrative LCP 200. In some cases, the LCP 200 may be considered as being an example of the right seed 22 (FIG. 2). In some cases, the LCP 200 may be considered as being an example of the left seed 24. In some instances, the components forming the LCP 200 may be split between the right seed 22 and the left seed 24.

In some cases, the LCP 200 may include a communication module 202, a pulse generator module 204, an electrical sensing module 206, a mechanical sensing module 208, a processing module 210, and a battery 218. Each of these modules may be similar to the modules 102, 104, 106, 108, and 110 of the LCP 100. Additionally, the battery 218 may be similar to the battery 112 of the LCP 100. In some cases, the LCP 200 may include leads such as leads 212. The leads 212 may include electrical wires that conduct electrical signals between the electrodes 214 and one or more of the modules located within housing 220. In some cases, the leads 212 may be connected to and extend away from the housing 220 of the LCP 200 in order to place electrodes 214 adjacent the atrial side 16 and/or the ventricle side 18 of the AV septum 12.

The mechanical sensing module 208, as with the mechanical sensing module 108, may contain or be electrically connected to one or more sensors, such as accelerometers, blood pressure sensors, heart sound sensors, blood-oxygen sensors, and/or other sensors which are configured to measure one or more mechanical/chemical parameters of the heart and/or patient. In some examples, one or more of the sensors may be located on the leads 212, but this is not required. In some examples, one or more of the sensors may be located in the housing 220.

FIGS. 9 through 11 illustrate deployment of an illustrative but non-limiting example of a two-part LCP 300. The illustrative LCP assembly 300 includes a right seed 302 that is configured to remain on the atrial side 16 of the AV septum 12, and a left seed 304 that is configured to extend through a passage 306 formed within the right seed 302. As illustrated, the left seed 304 includes a cylindrical or other shaped body 308. A first electrical conduit 310 extends distally from the cylindrical body 308 and includes a first electrode 312 that is coupled to the first electrical conduit 310. A second electrical conduit 314 extends distally from the cylindrical body 308 and includes a second electrode 316 that is coupled to the second electrical conduit 314. As illustrated, the first electrical conduit 310, the first electrode 312, the second electrical conduit 314 and the second electrode 316 are captured within a distal tip 318.

The distal tip 318 holds the first and second electrical conduits 310, 314 in the illustrated position for deployment. In some cases, the distal tip 318 is dissolvable upon exposure to blood. In some cases, the distal tip 318 may be formed of a crystallized material such as sugar that is safe for dissolving in the blood stream. Accordingly, the first and second electrical conduits 310, 314 may be held in a delivery configuration for delivery and subsequently may move into a deployment configuration (as shown for example in FIG. 11) once the distal tip 318 has dissolved. In some instances, the distal tip 318 may be considered as being a sweet tip.

In FIG. 10, the left seed 304 has been advanced through the passage 306 and through a passage 320 formed within the AV septum 12. In some instances, the distal tip 318 is configured to push through the AV septum 12 to form the passage 320. In some cases, a separate device may be extended through the AV septum 12 to form the passage 320 prior to insertion of the left seed 304. In FIG. 10, the distal tip 318 is still intact. Moving to FIG. 11, it can be seen that the distal tip 318 has dissolved or otherwise disappeared, permitting the first electrical conduit 310 to move into a position in which the first electrode 312 is in contact with the ventricle side 18 of the AV septum 12 and permitting the second electrical conduit 314 to move into a position in which the second electrode 316 is in contact with the ventricle side 18 of the AV septum 12.

FIG. 12 is a schematic view of another illustrative two-part LCP 400. The illustrative two-part LCP 400 includes a right seed 402 that is configured to remain on the atrial side 16 of the AV septum 12, and a left seed 404 that is configured to extend through a passage 406 formed within the right seed 402. As illustrated, the left seed 404 includes a cylindrical body 408. A first electrical conduit 410 extends distally from the cylindrical body 408 and includes a first electrode 412 that is coupled to the first electrical conduit 410. A second electrical conduit 414 extends distally from the cylindrical body 408 and includes a second electrode 416 that is coupled to the second electrical conduit 414. As illustrated, the first electrical conduit 410, the first electrode 412, the second electrical conduit 414 and the second electrode 416 are captured within a distal tip 418 that in some cases may be a sweet tip as discussed with respect to FIGS. 9 through 11. Once deployed, the distal tip 418 may dissolve or otherwise disappear, and the first electrical conduit 410 and the second electrical conduit 414 may be able to move into a deployed configuration in which the first electrode 412 and the second electrode 416 are positioned against the ventricle side 18 of the AV septum 12.

The cylindrical body 408 may include a proximal end 411 that is slidingly disposed within a chamber 422 that is formed within the right seed 402. It will be appreciated that the chamber 422 includes a distal end 424 that is configured to limit axial travel of the proximal end 411 of the left seed 404. Accordingly, the interaction between the proximal end 411 of the left seed 404 and the distal end 424 of the chamber 422 of the right seed 402 limits how far the left seed 404 can extend into the left ventricle LV. Once the distal tip 418 has dissolved or otherwise disappeared, the first and second electrical conduits 410 and 414 move into position against the ventricle side 18 of the AV septum 12, thereby limiting movement of the left seed 404 back towards the right atrium RA. Thus, the left seed 404 is locked in position relative to the right seed 402 and relative to the AV septum 12. In some embodiments, the left seed 404 may include a membrane 450 that may help to secure between the left seed 404 and the ventricle side 18 of the AV septum 12. In some cases, the membrane 450 may be formed of a flexible material such as silicone, and may be impregnated with a salt or other material that will cause the membrane 450 to swell upon exposure to blood. In some instances, the membrane 450 may have a folded down configuration for deployment of the left seed 404 and may subsequently revert to the expanded configuration shown in FIG. 12.

FIG. 13 is a schematic view of yet another illustrative two-part LCP 500. The illustrative LCP 500 includes a right seed 502 that is configured to remain on the atrial side 16 of the AV septum 12 and a left seed 504 that is configured to extend through a passage 506 formed within the right seed 502. As illustrated, the left seed 504 includes a cylindrical body 508. A first electrical conduit 510 extends distally from the cylindrical body 508 and includes a first electrode 512 that is coupled to the first electrical conduit 510. A second electrical conduit 514 extends distally from the cylindrical body 508 and includes a second electrode 516 that is coupled to the second electrical conduit 514. As illustrated, the first electrical conduit 510, the first electrode 512, the second electrical conduit 514 and the second electrode 516 are captured within a distal tip 518 that in some cases may be a sweet tip as discussed with respect to FIGS. 9 through 11.

In the example shown, the cylindrical body 508 of the left seed 504 includes a ratchet section 530 that is configured to interact with a corresponding ratchet section 532 disposed within the passage 506 formed within the right seed 502. In order to implant the LCP 500, the LCP 500 may be delivered to the right atrium RA with the left seed 504 disposed within the right seed 502 as illustrated, i.e., with the ratchet section 530 positioned outside of the right seed 502. Alternatively, the left seed 504 may be delivered to the right atrium RA and then the right seed 502 may be advanced over the left seed 504.

Once the left seed 504 has been advanced through the AV septum 12, and the distal tip 518 has dissolved or otherwise disappeared, the electrical conduits 510 and 514 may move the electrodes 512 and 516, respectively, into position against the ventricle side 18 of the AV septum 12. The left seed 504 may then be pulled back through the right seed 502 such that the ratchet section 530 engages the ratchet section 532. The ratchet sections 530 and 532 may be configured to permit the ratchet section 530 to move right to left (in the illustrated orientation), relative to the ratchet section 532 but not permit the ratchet section 530 to move left to right relative to the ratchet section 532. It will be appreciated that FIG. 13 is not to scale, and that the relative dimensions may vary in order to accommodate a particular patient's cardiac architecture.

In some embodiments, the left seed 504 may include a membrane 550 that may help to secure between the left seed 504 and the ventricle side 18 of the AV septum 12 and prevent blood from moving towards the right atrium RA after removal of a deployment device. In some cases, the membrane 550 may be formed of a flexible material such as silicone, and may be impregnated with a salt or other material that will cause the membrane 550 to swell upon exposure to blood. In some instances, the membrane 550 may have a folded down configuration for deployment of the left seed 504 and may subsequently revert to the expanded configuration shown in FIG. 13.

FIG. 14 is a schematic view of another illustrative two-part LCP 600. The illustrative LCP 600 includes a right seed 602 that is configured to remain on the atrial side 16 of the AV septum 12, and a left seed 604 that is configured to extend through a passage 606 formed within the right seed 602. As illustrated, the left seed 604 includes a cylindrical body 608. A first electrical conduit 610 extends distally from the cylindrical body 608 and includes a first electrode 612 that is coupled to the first electrical conduit 610. A second electrical conduit 614 extends distally from the cylindrical body 608 and includes a second electrode 616 that is coupled to the second electrical conduit 614. As illustrated, the first electrical conduit 610, the first electrode 612, the second electrical conduit 614 and the second electrode 616 are captured within a distal tip 618 that in some cases may be a sweet tip.

In some cases, the cylindrical body 608 of the left seed 604 may include a threaded portion 640 that threadedly engages a corresponding threaded portion 642 formed within the passage 606. Accordingly, advancement of the left seed 604 relative to the right seed 602 may be closely controlled. Once the left seed 604 has been deployed, the distal tip 618 may dissolve or otherwise disappear, and the first electrical conduit 610 and the second electrical conduit 614 may be able to move into a deployed configuration in which the first electrode 612 and the second electrode 616 are positioned against the ventricle side 18 of the AV septum 12. The left seed 604 may then be moved backward relative to the right seed 602 in order to lock the left seed 604 in place relative to the AV septum 12 and relative to the right seed 602 by rotating the left seed 604 in an opposite direction to that used to advance the left seed 604. In some cases, the threaded portion 642 may include a vinyl bump or other structure 644 that serves to lock the left seed 604 in position and not permit undesired movement after implantation.

In some embodiments, the left seed 604 may include a membrane 650 that may help to secure between the left seed 504 and the ventricle side 18 of the AV septum 12. In some cases, the membrane 550 may be formed of a flexible material such as silicone, and may be impregnated with a salt or other material that will cause the membrane 650 to swell upon exposure to blood. In some instances, the membrane 650 may have a folded down configuration for deployment of the left seed 604 and may subsequently revert to the expanded configuration shown in FIG. 14.

FIG. 15 is a flow diagram showing an illustrative method of deploying a leadless pacing and sensing assembly proximate a patient's atrioventricular septum. The leadless pacing and sensing assembly may include a right atrial leadless cardiac pacemaker (LCP) and a left ventricular leadless cardiac pacemaker (LCP). A delivery catheter may be advanced through the patient's vasculature until a distal end of the delivery catheter is proximate an atrial side of the atrioventricular septum. The right atrial LCP may be disposed within a distal region of the delivery catheter as generally indicated at block 700. A deployment device may be advanced past the right atrial LCP and through the atrioventricular septum. The left ventricular LCP, sometimes secured to the deployment device, may be passed past the right atrial LCP and disposed in the left ventricle and proximate a ventricular side of the atrioventricular septum as generally seen at block 702. In some cases, the relative spacing and/or positioning of the right atrial LCP and the left ventricular LCP may be adjusted to improve pacing and/or sensing performance of the right atrial LCP and/or the left ventricular LCP by, for example, improving contact between one or more electrodes and the atrioventricular septum. The right atrial LCP and/or the left ventricular LCP may, for example, be activated to test performance before their final positions are secured. As indicated at block 704, the left ventricular LCP may be secured to the right atrial LCP. In some instances, the left ventricular LCP may then be released from the deployment device. The deployment device may be withdrawn as seen at block 706. The delivery catheter may be withdrawn as indicated at block 708. In some cases, withdrawing the delivery catheter may release the right atrial LCP.

Those skilled in the art will recognize that the present disclosure may be manifested in a variety of forms other than the specific examples described and contemplated herein. For instance, as described herein, various examples include one or more modules described as performing various functions. However, other examples may include additional modules that split the described functions up over more modules than that described herein. Additionally, other examples may consolidate the described functions into fewer modules. Accordingly, departure in form and detail may be made without departing from the scope and spirit of the present disclosure as described in the appended claims.

Claims

1. An implantable medical device (IMD) configured for deployment at a patient's atrioventricular septum in order to sense and/or pace a patient's heart, the atrioventricular septum of the patient's heart having an atrial facing side defining part of the right atrium of the patient's heart and a ventricle facing side defining part of the left ventricle of the patient's heart, the IMD comprising:

a first component configured to be positioned at least in part in the right atrium of the patient's heart proximate the atrioventricular septum once the IMD is implanted, the first component comprising: a housing; a power source disposed within the housing; and circuitry disposed within the housing and operably coupled to the power source; one or more electrodes operatively coupled to the circuitry for pacing the atrial facing side of the patient's heart; and a passageway defined by the housing;
a second component configured to be positioned at least in part in the left ventricle of the patient's heart once the IMD is implanted, wherein the first component and the second component are configured such that the second component is translatable in its entirety relative to the first component, the second component is translatable through at least part of the passageway defined by the housing of the first component during deployment of the IMD and is configured to extend through the patient's atrioventricular septum and into the left ventricle of the patient's heart, the second component comprising: a housing; two or more electrodes for sensing and/or pacing the left ventricle of the patient's heart.

2. The IMD of claim 1, wherein the two or more electrodes of the second component are operably coupled to the circuitry of the first component.

3. The IMD of claim 1, wherein at least one of the two or more electrodes of the second component are configured to engage the ventricle facing side of the atrioventricular septum of the patient's heart once the IMD is implanted laterally where the second component is configured to extend through the patient's atrioventricular septum and into the left ventricle of the patient's heart.

4. The IMD of claim 1, wherein at least one of the two or more electrodes of the first component is configured to engage the atrial facing side of the atrioventricular septum of the patient's heart once the IMD is implanted.

5. The IMD of claim 1, wherein at least part of the second component is configured to move from a contracted state to an expanded state, wherein during implantation of the IMD, the second component is configured to pass through the atrioventricular septum in the contracted state and then move to the expanded state once in the left ventricle of the patient's heart.

6. The IMD of claim 5, wherein in the expanded state, the second component is configured to extend laterally beyond a lateral extent of where the second component would extend through the patient's atrioventricular septum and into the left ventricle of the patient's heart before engaging the left ventricle facing side of the atrioventricular septum of the patient's heart.

7. The IMD of claim 1, wherein the first component is configured to extend laterally beyond the lateral extent of the passageway defined by the housing with one or more of the electrodes of the first component configured to engage the atrial facing side of the atrioventricular septum of the patient's heart once the IMD is implanted.

8. The IMD of claim 1, wherein the second component is configured to cut a passage through the atrioventricular septum while the IMD is implanted.

9. The IMD of claim 1, wherein the second component is mechanically coupled to the first component through the passageway via a connecting member.

10. The IMD of claim 9, wherein the connecting member is part of the second component, and forms an interference fit with the first component.

11. The IMD of claim 9, wherein the connecting member is part of the first component, and forms an interference fit with the first component.

12. The IMD of claim 1, wherein the first component comprises a fixation element configured to secure the first component to the atrioventricular septum of the patient's heart.

13. The IMD of claim 1, wherein the second component comprises a fixation element configured to secure the second component to the atrioventricular septum of the patient's heart.

14. An implantable medical device (IMD) configured for deployment at a patient's atrioventricular septum, the atrioventricular septum of the patient's heart having an atrial facing side defining part of the right atrium of the patient's heart and a ventricle facing side defining part of the left ventricle of the patient's heart, the IMD comprising:

a right seed that is configured to remain on the atrial facing side of the right atrium of the patient's heart for pacing the atrial facing side of the patient's heart, the right seed comprising: a right seed housing; a battery disposed within the right seed housing; control electronics disposed within the right seed housing; one or more electrodes operatively coupled to the control electronics for pacing the atrial facing side of the patient's heart; and a passageway defined by the right seed housing;
a left seed that is configured to translate in its entirety relative to the right seed, the left seed translating through at least part of the passageway defined by the right seed housing during deployment of the IMD, through the patient's atrioventricular septum, and into the left ventricle of the patient's heart, the left seed comprising: a body having a first end portion, a second end portion and a connecting portion connecting the first end portion to the second end portion; at least part of the first end portion configured to be connected to the right seed once the IMD is implanted; at least part of the second end portion of the body of the left seed configured to extend into the left ventricle of the patient's heart once the IMD is implanted; the connecting portion configured to extend through a passage that passes through the atrioventricular septum; and the second end portion of the body of the left seed including one or more electrodes for sensing and/or pacing the left ventricle of the patient's heart, the second end portion extending laterally beyond a lateral extent of the connecting portion such that at least one of the one or more electrodes of the second end portion is configured to engage the ventricle facing side of the atrioventricular septum of the patient's heart laterally beyond the lateral extent of the connecting portion once the IMD is implanted.

15. The IMD of claim 14, wherein the one or more electrodes of the second end portion of the left seed are operatively connected to the control electronics of the right seed through the connecting portion of the left seed.

16. The IMD of claim 14, wherein at least part of the second end portion is configured to move from a contracted state to an expanded state during deployment of the IMD.

17. A method of deploying a leadless pacing and sensing assembly proximate a patient's atrioventricular septum, the leadless pacing and sensing assembly including a right atrial leadless cardiac pacemaker (LCP) and a left ventricular leadless cardiac pacemaker (LCP), the method comprising:

advancing a delivery catheter through the patient's vasculature until a distal end of the delivery catheter is proximate an atrial side of the atrioventricular septum, the right atrial LCP disposed within a distal region of the delivery catheter;
advancing a deployment device through a passageway extending through the right atrial LCP and through the atrioventricular septum, the left ventricular LCP secured to the deployment device such that the left ventricular LCP extends through the right atrial LCP and is disposed proximate a ventricular side of the atrioventricular septum, the left ventricular LCP including one or more electrodes configured to extend laterally past a lateral extent of the passageway and to engage the ventricle facing side of the atrioventricular septum of the patient's heart;
securing the left ventricular LCP to the right atrial LCP; and
withdrawing the deployment device.

18. The method of claim 17, further comprising withdrawing the delivery catheter.

Referenced Cited
U.S. Patent Documents
3835864 September 1974 Rasor et al.
3943936 March 16, 1976 Rasor et al.
4142530 March 6, 1979 Wittkampf
4151513 April 24, 1979 Menken et al.
4157720 June 12, 1979 Greatbatch
RE30366 August 12, 1980 Rasor et al.
4243045 January 6, 1981 Maas
4250884 February 17, 1981 Hartlaub et al.
4256115 March 17, 1981 Bilitch
4263919 April 28, 1981 Levin
4310000 January 12, 1982 Lindemans
4312354 January 26, 1982 Walters
4323081 April 6, 1982 Wiebusch
4357946 November 9, 1982 Dutcher et al.
4365639 December 28, 1982 Goldreyer
4440173 April 3, 1984 Hudziak et al.
4476868 October 16, 1984 Thompson
4522208 June 11, 1985 Buffet
4537200 August 27, 1985 Widrow
4556063 December 3, 1985 Thompson et al.
4562841 January 7, 1986 Brockway et al.
4593702 June 10, 1986 Kepski et al.
4593955 June 10, 1986 Leiber
4630611 December 23, 1986 King
4635639 January 13, 1987 Hakala et al.
4674508 June 23, 1987 DeCote
4712554 December 15, 1987 Garson
4729376 March 8, 1988 DeCote
4754753 July 5, 1988 King
4759366 July 26, 1988 Callaghan
4776338 October 11, 1988 Lekholm et al.
4787389 November 29, 1988 Tarjan
4793353 December 27, 1988 Borkan
4819662 April 11, 1989 Heil et al.
4858610 August 22, 1989 Callaghan et al.
4886064 December 12, 1989 Strandberg
4887609 December 19, 1989 Cole, Jr.
4928688 May 29, 1990 Mower
4967746 November 6, 1990 Vandegriff
4987897 January 29, 1991 Funke
4989602 February 5, 1991 Sholder et al.
5012806 May 7, 1991 De Bellis
5036849 August 6, 1991 Hauck et al.
5040534 August 20, 1991 Mann et al.
5058581 October 22, 1991 Silvian
5078134 January 7, 1992 Heilman et al.
5109845 May 5, 1992 Yuuchi et al.
5113859 May 19, 1992 Funke
5113869 May 19, 1992 Nappholz et al.
5117824 June 2, 1992 Keimel et al.
5127401 July 7, 1992 Grevious et al.
5133353 July 28, 1992 Hauser
5144950 September 8, 1992 Stoop et al.
5170784 December 15, 1992 Ramon et al.
5179945 January 19, 1993 Van Hofwegen et al.
5193539 March 16, 1993 Schulman et al.
5193540 March 16, 1993 Schulman et al.
5241961 September 7, 1993 Henry
5243977 September 14, 1993 Trabucco et al.
5259387 November 9, 1993 dePinto
5269326 December 14, 1993 Verrier
5284136 February 8, 1994 Hauck et al.
5300107 April 5, 1994 Stokes et al.
5301677 April 12, 1994 Hsung
5305760 April 26, 1994 McKown et al.
5312439 May 17, 1994 Loeb
5313953 May 24, 1994 Yomtov et al.
5314459 May 24, 1994 Swanson et al.
5318597 June 7, 1994 Hauck et al.
5324316 June 28, 1994 Schulman et al.
5331966 July 26, 1994 Bennett et al.
5334222 August 2, 1994 Salo et al.
5342408 August 30, 1994 Decoriolis et al.
5370667 December 6, 1994 Alt
5372606 December 13, 1994 Lang et al.
5376106 December 27, 1994 Stahmann et al.
5383915 January 24, 1995 Adams
5388578 February 14, 1995 Yomtov et al.
5404877 April 11, 1995 Nolan et al.
5405367 April 11, 1995 Schulman et al.
5411031 May 2, 1995 Yomtov
5411525 May 2, 1995 Swanson et al.
5411535 May 2, 1995 Fujii et al.
5456691 October 10, 1995 Snell
5458622 October 17, 1995 Alt
5466246 November 14, 1995 Silvian
5468254 November 21, 1995 Hahn et al.
5472453 December 5, 1995 Alt
5522866 June 4, 1996 Fernald
5540727 July 30, 1996 Tockman et al.
5545186 August 13, 1996 Olson et al.
5545202 August 13, 1996 Dahl et al.
5571146 November 5, 1996 Jones et al.
5591214 January 7, 1997 Lu
5620466 April 15, 1997 Haefner et al.
5634938 June 3, 1997 Swanson et al.
5649968 July 22, 1997 Alt et al.
5662688 September 2, 1997 Haefner et al.
5674259 October 7, 1997 Gray
5683426 November 4, 1997 Greenhut et al.
5683432 November 4, 1997 Goedeke et al.
5706823 January 13, 1998 Wodlinger
5709215 January 20, 1998 Perttu et al.
5720770 February 24, 1998 Nappholz et al.
5728154 March 17, 1998 Crossett et al.
5741314 April 21, 1998 Daly et al.
5741315 April 21, 1998 Lee et al.
5752976 May 19, 1998 Duffin et al.
5752977 May 19, 1998 Grevious et al.
5755736 May 26, 1998 Gillberg et al.
5759199 June 2, 1998 Snell et al.
5774501 June 30, 1998 Halpern et al.
5792195 August 11, 1998 Carlson et al.
5792202 August 11, 1998 Rueter
5792203 August 11, 1998 Schroeppel
5792205 August 11, 1998 Alt et al.
5792208 August 11, 1998 Gray
5814089 September 29, 1998 Stokes et al.
5827216 October 27, 1998 Igo et al.
5836985 November 17, 1998 Goyal et al.
5836987 November 17, 1998 Baumann et al.
5842977 December 1, 1998 Lesho et al.
5855593 January 5, 1999 Olson et al.
5873894 February 23, 1999 Vandegriff et al.
5891184 April 6, 1999 Lee et al.
5897586 April 27, 1999 Molina
5899876 May 4, 1999 Flower
5899928 May 4, 1999 Sholder et al.
5919214 July 6, 1999 Ciciarelli et al.
5935078 August 10, 1999 Feierbach
5941906 August 24, 1999 Barreras et al.
5944744 August 31, 1999 Paul et al.
5954757 September 21, 1999 Gray
5978713 November 2, 1999 Prutchi et al.
5991660 November 23, 1999 Goyal
5991661 November 23, 1999 Park et al.
5999848 December 7, 1999 Gord et al.
5999857 December 7, 1999 Weijand et al.
6016445 January 18, 2000 Baura
6026320 February 15, 2000 Carlson et al.
6029085 February 22, 2000 Olson et al.
6041250 March 21, 2000 dePinto
6044298 March 28, 2000 Salo et al.
6044300 March 28, 2000 Gray
6055454 April 25, 2000 Heemels
6073050 June 6, 2000 Griffith
6076016 June 13, 2000 Feierbach
6077236 June 20, 2000 Cunningham
6080187 June 27, 2000 Alt et al.
6083248 July 4, 2000 Thompson
6106551 August 22, 2000 Crossett et al.
6115636 September 5, 2000 Ryan
6128526 October 3, 2000 Stadler et al.
6141581 October 31, 2000 Olson et al.
6141588 October 31, 2000 Cox et al.
6141592 October 31, 2000 Pauly
6144879 November 7, 2000 Gray
6162195 December 19, 2000 Igo et al.
6164284 December 26, 2000 Schulman et al.
6167310 December 26, 2000 Grevious
6201993 March 13, 2001 Kruse et al.
6208894 March 27, 2001 Schulman et al.
6211799 April 3, 2001 Post et al.
6221011 April 24, 2001 Bardy
6240316 May 29, 2001 Richmond et al.
6240317 May 29, 2001 Villaseca et al.
6256534 July 3, 2001 Dahl
6259947 July 10, 2001 Olson et al.
6266558 July 24, 2001 Gozani et al.
6266567 July 24, 2001 Ishikawa et al.
6270457 August 7, 2001 Bardy
6272377 August 7, 2001 Sweeney et al.
6273856 August 14, 2001 Sun et al.
6277072 August 21, 2001 Bardy
6280380 August 28, 2001 Bardy
6285907 September 4, 2001 Kramer et al.
6292698 September 18, 2001 Duffin et al.
6295473 September 25, 2001 Rosar
6297943 October 2, 2001 Carson
6298271 October 2, 2001 Weijand
6307751 October 23, 2001 Bodony et al.
6312378 November 6, 2001 Bardy
6315721 November 13, 2001 Schulman et al.
6336903 January 8, 2002 Bardy
6345202 February 5, 2002 Richmond et al.
6351667 February 26, 2002 Godie
6351669 February 26, 2002 Hartley et al.
6353759 March 5, 2002 Hartley et al.
6358203 March 19, 2002 Bardy
6361780 March 26, 2002 Ley et al.
6368284 April 9, 2002 Bardy
6371922 April 16, 2002 Baumann et al.
6398728 June 4, 2002 Bardy
6400982 June 4, 2002 Sweeney et al.
6400990 June 4, 2002 Silvian
6408208 June 18, 2002 Sun
6409674 June 25, 2002 Brockway et al.
6411848 June 25, 2002 Kramer et al.
6424865 July 23, 2002 Ding
6434429 August 13, 2002 Kraus et al.
6438410 August 20, 2002 Hsu et al.
6438417 August 20, 2002 Rockwell et al.
6438421 August 20, 2002 Stahmann et al.
6440066 August 27, 2002 Bardy
6441747 August 27, 2002 Khair et al.
6442426 August 27, 2002 Kroll
6442432 August 27, 2002 Lee
6443891 September 3, 2002 Grevious
6445953 September 3, 2002 Bulkes et al.
6453200 September 17, 2002 Koslar
6459929 October 1, 2002 Hopper et al.
6470215 October 22, 2002 Kraus et al.
6471645 October 29, 2002 Warkentin et al.
6480745 November 12, 2002 Nelson et al.
6487443 November 26, 2002 Olson et al.
6490487 December 3, 2002 Kraus et al.
6498951 December 24, 2002 Larson et al.
6507755 January 14, 2003 Gozani et al.
6507759 January 14, 2003 Prutchi et al.
6512940 January 28, 2003 Brabec et al.
6522915 February 18, 2003 Ceballos et al.
6526311 February 25, 2003 Begemann
6539253 March 25, 2003 Thompson et al.
6542775 April 1, 2003 Ding et al.
6553258 April 22, 2003 Stahmann et al.
6561975 May 13, 2003 Pool et al.
6564807 May 20, 2003 Schulman et al.
6574506 June 3, 2003 Kramer et al.
6584351 June 24, 2003 Ekwall
6584352 June 24, 2003 Combs et al.
6597948 July 22, 2003 Rockwell et al.
6597951 July 22, 2003 Kramer et al.
6622046 September 16, 2003 Fraley et al.
6628985 September 30, 2003 Sweeney et al.
6647292 November 11, 2003 Bardy et al.
6666844 December 23, 2003 Igo et al.
6689117 February 10, 2004 Sweeney et al.
6690959 February 10, 2004 Thompson
6694189 February 17, 2004 Begemann
6704602 March 9, 2004 Berg et al.
6718212 April 6, 2004 Parry et al.
6721597 April 13, 2004 Bardy et al.
6738670 May 18, 2004 Almendinger et al.
6746797 June 8, 2004 Benson et al.
6749566 June 15, 2004 Russ
6758810 July 6, 2004 Lebel et al.
6763269 July 13, 2004 Cox
6778860 August 17, 2004 Ostroff et al.
6788971 September 7, 2004 Sloman et al.
6788974 September 7, 2004 Bardy et al.
6804558 October 12, 2004 Haller et al.
6807442 October 19, 2004 Myklebust et al.
6847844 January 25, 2005 Sun et al.
6871095 March 22, 2005 Stahmann et al.
6878112 April 12, 2005 Linberg et al.
6885889 April 26, 2005 Chinchoy
6892094 May 10, 2005 Ousdigian et al.
6897788 May 24, 2005 Khair et al.
6904315 June 7, 2005 Panken et al.
6922592 July 26, 2005 Thompson et al.
6931282 August 16, 2005 Esler
6934585 August 23, 2005 Schloss et al.
6957107 October 18, 2005 Rogers et al.
6978176 December 20, 2005 Lattouf
6985773 January 10, 2006 Von Arx et al.
6990375 January 24, 2006 Kloss et al.
7001366 February 21, 2006 Ballard
7003350 February 21, 2006 Denker et al.
7006864 February 28, 2006 Echt et al.
7013178 March 14, 2006 Reinke et al.
7027871 April 11, 2006 Burnes et al.
7050849 May 23, 2006 Echt et al.
7060031 June 13, 2006 Webb et al.
7063693 June 20, 2006 Guenst
7082336 July 25, 2006 Ransbury et al.
7085606 August 1, 2006 Flach et al.
7092758 August 15, 2006 Sun et al.
7110824 September 19, 2006 Amundson et al.
7120504 October 10, 2006 Osypka
7130681 October 31, 2006 Gebhardt et al.
7139613 November 21, 2006 Reinke et al.
7142912 November 28, 2006 Wagner et al.
7146225 December 5, 2006 Guenst et al.
7146226 December 5, 2006 Lau et al.
7149581 December 12, 2006 Goedeke
7149588 December 12, 2006 Lau et al.
7158839 January 2, 2007 Lau
7162307 January 9, 2007 Patrias
7164952 January 16, 2007 Lau et al.
7177700 February 13, 2007 Cox
7181505 February 20, 2007 Haller et al.
7184830 February 27, 2007 Echt et al.
7186214 March 6, 2007 Ness
7191015 March 13, 2007 Lamson et al.
7200437 April 3, 2007 Nabutovsky et al.
7200439 April 3, 2007 Zdeblick et al.
7206423 April 17, 2007 Feng et al.
7209785 April 24, 2007 Kim et al.
7209790 April 24, 2007 Thompson et al.
7211884 May 1, 2007 Davis et al.
7212871 May 1, 2007 Morgan
7226440 June 5, 2007 Gelfand et al.
7228183 June 5, 2007 Sun et al.
7236821 June 26, 2007 Cates et al.
7236829 June 26, 2007 Farazi et al.
7254448 August 7, 2007 Almendinger et al.
7260436 August 21, 2007 Kilgore et al.
7270669 September 18, 2007 Sra
7272448 September 18, 2007 Morgan et al.
7277755 October 2, 2007 Falkenberg et al.
7280872 October 9, 2007 Mosesov et al.
7288096 October 30, 2007 Chin
7289847 October 30, 2007 Gill et al.
7289852 October 30, 2007 Helfinstine et al.
7289853 October 30, 2007 Campbell et al.
7289855 October 30, 2007 Nghiem et al.
7302294 November 27, 2007 Kamath et al.
7305266 December 4, 2007 Kroll
7310556 December 18, 2007 Bulkes
7319905 January 15, 2008 Morgan et al.
7321798 January 22, 2008 Muhlenberg et al.
7333853 February 19, 2008 Mazar et al.
7336994 February 26, 2008 Hettrick et al.
7347819 March 25, 2008 Lebel et al.
7366572 April 29, 2008 Heruth et al.
7373207 May 13, 2008 Lattouf
7384403 June 10, 2008 Sherman
7386342 June 10, 2008 Falkenberg et al.
7392090 June 24, 2008 Sweeney et al.
7406105 July 29, 2008 DelMain et al.
7406349 July 29, 2008 Seeberger et al.
7410497 August 12, 2008 Hastings et al.
7425200 September 16, 2008 Brockway et al.
7433739 October 7, 2008 Salys et al.
7448999 November 11, 2008 Karicherla
7496409 February 24, 2009 Greenhut et al.
7496410 February 24, 2009 Heil
7502652 March 10, 2009 Gaunt et al.
7512448 March 31, 2009 Malick et al.
7515969 April 7, 2009 Tockman et al.
7526342 April 28, 2009 Chin et al.
7529589 May 5, 2009 Williams et al.
7532933 May 12, 2009 Hastings et al.
7536222 May 19, 2009 Bardy et al.
7536224 May 19, 2009 Ritscher et al.
7539541 May 26, 2009 Quiles et al.
7544197 June 9, 2009 Kelsch et al.
7558631 July 7, 2009 Cowan et al.
7565195 July 21, 2009 Kroll et al.
7584002 September 1, 2009 Burnes et al.
7590455 September 15, 2009 Heruth et al.
7606621 October 20, 2009 Brisken et al.
7610088 October 27, 2009 Chinchoy
7610092 October 27, 2009 Cowan et al.
7610099 October 27, 2009 Almendinger et al.
7610104 October 27, 2009 Kaplan et al.
7616991 November 10, 2009 Mann et al.
7617001 November 10, 2009 Penner et al.
7617007 November 10, 2009 Williams et al.
7630767 December 8, 2009 Poore et al.
7634313 December 15, 2009 Kroll et al.
7637867 December 29, 2009 Zdeblick
7640060 December 29, 2009 Zdeblick
7647109 January 12, 2010 Hastings et al.
7650186 January 19, 2010 Hastings et al.
7657311 February 2, 2010 Bardy et al.
7668596 February 23, 2010 Von Arx et al.
7682316 March 23, 2010 Anderson et al.
7691047 April 6, 2010 Ferrari
7702392 April 20, 2010 Echt et al.
7713194 May 11, 2010 Zdeblick
7713195 May 11, 2010 Zdeblick
7729783 June 1, 2010 Michels et al.
7734333 June 8, 2010 Ghanem et al.
7734343 June 8, 2010 Ransbury et al.
7738958 June 15, 2010 Zdeblick et al.
7738964 June 15, 2010 Von Arx et al.
7742812 June 22, 2010 Ghanem et al.
7742816 June 22, 2010 Masoud et al.
7742822 June 22, 2010 Masoud et al.
7743151 June 22, 2010 Vallapureddy et al.
7747335 June 29, 2010 Williams
7751881 July 6, 2010 Cowan et al.
7758521 July 20, 2010 Morris et al.
7761150 July 20, 2010 Ghanem et al.
7761164 July 20, 2010 Verhoef et al.
7765001 July 27, 2010 Echt et al.
7769452 August 3, 2010 Ghanem et al.
7783362 August 24, 2010 Whitehurst et al.
7792588 September 7, 2010 Harding
7797059 September 14, 2010 Bornzin et al.
7801596 September 21, 2010 Fischell et al.
7809438 October 5, 2010 Echt et al.
7840281 November 23, 2010 Kveen et al.
7844331 November 30, 2010 Li et al.
7844348 November 30, 2010 Swoyer et al.
7846088 December 7, 2010 Ness
7848815 December 7, 2010 Brisken et al.
7848823 December 7, 2010 Drasler et al.
7860455 December 28, 2010 Fukumoto et al.
7871433 January 18, 2011 Lattouf
7877136 January 25, 2011 Moffitt et al.
7877142 January 25, 2011 Moaddeb et al.
7881786 February 1, 2011 Jackson
7881798 February 1, 2011 Miesel et al.
7881810 February 1, 2011 Chitre et al.
7890173 February 15, 2011 Brisken et al.
7890181 February 15, 2011 Denzene et al.
7890192 February 15, 2011 Kelsch et al.
7894885 February 22, 2011 Bartal et al.
7894894 February 22, 2011 Stadler et al.
7894907 February 22, 2011 Cowan et al.
7894910 February 22, 2011 Cowan et al.
7894915 February 22, 2011 Chitre et al.
7899537 March 1, 2011 Kroll et al.
7899541 March 1, 2011 Cowan et al.
7899542 March 1, 2011 Cowan et al.
7899554 March 1, 2011 Williams et al.
7901360 March 8, 2011 Yang et al.
7904170 March 8, 2011 Harding
7907993 March 15, 2011 Ghanem et al.
7920928 April 5, 2011 Yang et al.
7925343 April 12, 2011 Min et al.
7930022 April 19, 2011 Zhang et al.
7930040 April 19, 2011 Kelsch et al.
7937135 May 3, 2011 Ghanem et al.
7937148 May 3, 2011 Jacobson
7937161 May 3, 2011 Hastings et al.
7941214 May 10, 2011 Kleckner et al.
7945333 May 17, 2011 Jacobson
7946997 May 24, 2011 Hübinette
7949404 May 24, 2011 Hill
7949405 May 24, 2011 Feher
7953486 May 31, 2011 Daum et al.
7953493 May 31, 2011 Fowler et al.
7962202 June 14, 2011 Bhunia
7974702 July 5, 2011 Fain et al.
7979136 July 12, 2011 Young et al.
7983753 July 19, 2011 Severin
7991467 August 2, 2011 Markowitz et al.
7991471 August 2, 2011 Ghanem et al.
7996087 August 9, 2011 Cowan et al.
8000791 August 16, 2011 Sunagawa et al.
8000807 August 16, 2011 Morris et al.
8001975 August 23, 2011 DiSilvestro et al.
8002700 August 23, 2011 Ferek-Petric et al.
8010209 August 30, 2011 Jacobson
8019419 September 13, 2011 Panescu et al.
8019434 September 13, 2011 Quiles et al.
8027727 September 27, 2011 Freeberg
8027729 September 27, 2011 Sunagawa et al.
8032219 October 4, 2011 Neumann et al.
8036743 October 11, 2011 Savage et al.
8046079 October 25, 2011 Bange et al.
8046080 October 25, 2011 Von Arx et al.
8050297 November 1, 2011 Delmain et al.
8050759 November 1, 2011 Stegemann et al.
8050774 November 1, 2011 Kveen et al.
8055345 November 8, 2011 Li et al.
8055350 November 8, 2011 Roberts
8060212 November 15, 2011 Rios et al.
8065018 November 22, 2011 Haubrich et al.
8073542 December 6, 2011 Doerr
8078278 December 13, 2011 Penner
8078283 December 13, 2011 Cowan et al.
8095123 January 10, 2012 Gray
8102789 January 24, 2012 Rosar et al.
8103359 January 24, 2012 Reddy
8103361 January 24, 2012 Moser
8112148 February 7, 2012 Giftakis et al.
8114021 February 14, 2012 Robertson et al.
8121680 February 21, 2012 Falkenberg et al.
8123684 February 28, 2012 Zdeblick
8126545 February 28, 2012 Flach et al.
8131334 March 6, 2012 Lu et al.
8140161 March 20, 2012 Willerton et al.
8150521 April 3, 2012 Crowley et al.
8160672 April 17, 2012 Kim et al.
8160702 April 17, 2012 Mann et al.
8160704 April 17, 2012 Freeberg
8165694 April 24, 2012 Carbanaru et al.
8175715 May 8, 2012 Cox
8180451 May 15, 2012 Hickman et al.
8185213 May 22, 2012 Kveen et al.
8187161 May 29, 2012 Li et al.
8195293 June 5, 2012 Limousin et al.
8204595 June 19, 2012 Pianca et al.
8204605 June 19, 2012 Hastings et al.
8209014 June 26, 2012 Doerr
8214043 July 3, 2012 Matos
8224244 July 17, 2012 Kim et al.
8229556 July 24, 2012 Li
8233985 July 31, 2012 Bulkes et al.
8265748 September 11, 2012 Liu et al.
8265757 September 11, 2012 Mass et al.
8262578 September 11, 2012 Bharmi et al.
8280521 October 2, 2012 Haubrich et al.
8285387 October 9, 2012 Utsi et al.
8290598 October 16, 2012 Boon et al.
8290600 October 16, 2012 Hastings et al.
8295939 October 23, 2012 Jacobson
8301254 October 30, 2012 Mosesov et al.
8315701 November 20, 2012 Cowan et al.
8315708 November 20, 2012 Berthelsdorf et al.
8321021 November 27, 2012 Kisker et al.
8321036 November 27, 2012 Brockway et al.
8332036 December 11, 2012 Hastings et al.
8335563 December 18, 2012 Stessman
8335568 December 18, 2012 Heruth et al.
8340750 December 25, 2012 Prakash et al.
8340780 December 25, 2012 Hastings et al.
8352025 January 8, 2013 Jacobson
8352028 January 8, 2013 Wenger
8352038 January 8, 2013 Mao et al.
8359098 January 22, 2013 Lund et al.
8364261 January 29, 2013 Stubbs et al.
8364276 January 29, 2013 Willis
8369959 February 5, 2013 Meskens
8369962 February 5, 2013 Abrahamson
8380320 February 19, 2013 Spital
8386051 February 26, 2013 Rys
8391981 March 5, 2013 Mosesov
8391990 March 5, 2013 Smith et al.
8406874 March 26, 2013 Liu et al.
8406879 March 26, 2013 Shuros et al.
8406886 March 26, 2013 Gaunt et al.
8412352 April 2, 2013 Griswold et al.
8417340 April 9, 2013 Goossen
8417341 April 9, 2013 Freeberg
8423149 April 16, 2013 Hennig
8428722 April 23, 2013 Verhoef et al.
8433402 April 30, 2013 Ruben et al.
8433409 April 30, 2013 Johnson et al.
8433420 April 30, 2013 Bange et al.
8447412 May 21, 2013 Dal Molin et al.
8452413 May 28, 2013 Young et al.
8457740 June 4, 2013 Osche
8457742 June 4, 2013 Jacobson
8457744 June 4, 2013 Janzig et al.
8457761 June 4, 2013 Wariar
8478407 July 2, 2013 Demmer et al.
8478408 July 2, 2013 Hastings et al.
8478431 July 2, 2013 Griswold et al.
8494632 July 23, 2013 Sun et al.
8504156 August 6, 2013 Bonner et al.
8509910 August 13, 2013 Sowder et al.
8515559 August 20, 2013 Roberts et al.
8525340 September 3, 2013 Eckhardt et al.
8527068 September 3, 2013 Ostroff
8532790 September 10, 2013 Griswold
8538526 September 17, 2013 Stahmann et al.
8541131 September 24, 2013 Lund et al.
8543205 September 24, 2013 Ostroff
8547248 October 1, 2013 Zdeblick et al.
8548605 October 1, 2013 Ollivier
8554333 October 8, 2013 Wu et al.
8565882 October 22, 2013 Matos
8565897 October 22, 2013 Regnier et al.
8571678 October 29, 2013 Wang
8577327 November 5, 2013 Makdissi et al.
8588926 November 19, 2013 Moore et al.
8612002 December 17, 2013 Faltys et al.
8615310 December 24, 2013 Khairkhahan et al.
8626280 January 7, 2014 Allavatam et al.
8626294 January 7, 2014 Sheldon et al.
8634908 January 21, 2014 Cowan
8634912 January 21, 2014 Bornzin et al.
8634919 January 21, 2014 Hou et al.
8639335 January 28, 2014 Peichel et al.
8644934 February 4, 2014 Hastings et al.
8649859 February 11, 2014 Smith et al.
8670842 March 11, 2014 Bornzin et al.
8676319 March 18, 2014 Knoll
8676335 March 18, 2014 Katoozi et al.
8700173 April 15, 2014 Edlund
8700181 April 15, 2014 Bornzin et al.
8705599 April 22, 2014 dal Molin et al.
8718766 May 6, 2014 Wahlberg
8718773 May 6, 2014 Willis et al.
8725260 May 13, 2014 Shuros et al.
8738133 May 27, 2014 Shuros et al.
8738147 May 27, 2014 Hastings et al.
8744555 June 3, 2014 Allavatam et al.
8744572 June 3, 2014 Greenhut et al.
8747314 June 10, 2014 Stahmann et al.
8755884 June 17, 2014 Demmer et al.
8758365 June 24, 2014 Bonner et al.
8768483 July 1, 2014 Schmitt et al.
8774572 July 8, 2014 Hamamoto
8781605 July 15, 2014 Bornzin et al.
8788035 July 22, 2014 Jacobson
8788053 July 22, 2014 Jacobson
8798740 August 5, 2014 Samade et al.
8798745 August 5, 2014 Jacobson
8798762 August 5, 2014 Fain et al.
8798770 August 5, 2014 Reddy
8805505 August 12, 2014 Roberts
8805528 August 12, 2014 Corndort
8812109 August 19, 2014 Blomqvist et al.
8818504 August 26, 2014 Bodner et al.
8827913 September 9, 2014 Havel et al.
8831747 September 9, 2014 Min et al.
8855789 October 7, 2014 Jacobson
8868186 October 21, 2014 Kroll
8886339 November 11, 2014 Faltys et al.
8903473 December 2, 2014 Rogers et al.
8903500 December 2, 2014 Smith et al.
8903513 December 2, 2014 Ollivier
8909336 December 9, 2014 Navarro-Paredes et al.
8914131 December 16, 2014 Bornzin et al.
8923795 December 30, 2014 Makdissi et al.
8923963 December 30, 2014 Bonner et al.
8938300 January 20, 2015 Rosero
8942806 January 27, 2015 Sheldon et al.
8958892 February 17, 2015 Khairkhahan et al.
8977358 March 10, 2015 Ewert et al.
8989873 March 24, 2015 Locsin
8996109 March 31, 2015 Karst et al.
9002467 April 7, 2015 Smith et al.
9008776 April 14, 2015 Cowan et al.
9008777 April 14, 2015 Dianaty et al.
9014818 April 21, 2015 Deterre et al.
9017341 April 28, 2015 Bornzin et al.
9020611 April 28, 2015 Khairkhahan et al.
9037262 May 19, 2015 Regnier et al.
9042984 May 26, 2015 Demmer et al.
9072911 July 7, 2015 Hastings et al.
9072913 July 7, 2015 Jacobson
9155882 October 13, 2015 Grubac et al.
9168372 October 27, 2015 Fain
9168380 October 27, 2015 Greenhut et al.
9168383 October 27, 2015 Jacobson et al.
9180285 November 10, 2015 Moore et al.
9192774 November 24, 2015 Jacobson
9205225 December 8, 2015 Khairkhahan et al.
9216285 December 22, 2015 Boling et al.
9216293 December 22, 2015 Berthiaume et al.
9216298 December 22, 2015 Jacobson
9227077 January 5, 2016 Jacobson
9238145 January 19, 2016 Wenzel et al.
9242102 January 26, 2016 Khairkhahan et al.
9242113 January 26, 2016 Smith et al.
9248300 February 2, 2016 Rys et al.
9265436 February 23, 2016 Min et al.
9265962 February 23, 2016 Dianaty et al.
9272155 March 1, 2016 Ostroff
9278218 March 8, 2016 Karst et al.
9278229 March 8, 2016 Reinke et al.
9283381 March 15, 2016 Grubac et al.
9283382 March 15, 2016 Berthiaume et al.
9289612 March 22, 2016 Sambelashvili et al.
9302115 April 5, 2016 Molin et al.
9333364 May 10, 2016 Echt et al.
9358387 June 7, 2016 Suwito et al.
9358400 June 7, 2016 Jacobson
9364675 June 14, 2016 Deterre et al.
9370663 June 21, 2016 Moulder
9375580 June 28, 2016 Bonner et al.
9375581 June 28, 2016 Baru et al.
9381365 July 5, 2016 Kibler et al.
9393424 July 19, 2016 Demmer et al.
9393436 July 19, 2016 Doerr
9399139 July 26, 2016 Demmer et al.
9399140 July 26, 2016 Cho et al.
9409033 August 9, 2016 Jacobson
9427594 August 30, 2016 Bornzin et al.
9433368 September 6, 2016 Stahmann et al.
9433780 September 6, 2016 Régnier et al.
9457193 October 4, 2016 Klimovitch et al.
9492668 November 15, 2016 Sheldon et al.
9492669 November 15, 2016 Demmer et al.
9492674 November 15, 2016 Schmidt et al.
9492677 November 15, 2016 Greenhut et al.
9511233 December 6, 2016 Sambelashvili
9511236 December 6, 2016 Varady et al.
9511237 December 6, 2016 Deterre et al.
9522276 December 20, 2016 Shen et al.
9522280 December 20, 2016 Fishler et al.
9526522 December 27, 2016 Wood et al.
9526891 December 27, 2016 Eggen et al.
9526909 December 27, 2016 Stahmann et al.
9533163 January 3, 2017 Klimovitch et al.
9561382 February 7, 2017 Persson et al.
9566012 February 14, 2017 Greenhut et al.
9636511 May 2, 2017 Carney et al.
20020032470 March 14, 2002 Linberg
20020035376 March 21, 2002 Bardy et al.
20020035377 March 21, 2002 Bardy et al.
20020035378 March 21, 2002 Bardy et al.
20020035380 March 21, 2002 Rissmann et al.
20020035381 March 21, 2002 Bardy et al.
20020042629 April 11, 2002 Bardy et al.
20020042630 April 11, 2002 Bardy et al.
20020042634 April 11, 2002 Bardy et al.
20020049475 April 25, 2002 Bardy et al.
20020052636 May 2, 2002 Bardy et al.
20020068958 June 6, 2002 Bardy et al.
20020072773 June 13, 2002 Bardy et al.
20020082665 June 27, 2002 Haller et al.
20020091414 July 11, 2002 Bardy et al.
20020095196 July 18, 2002 Linberg
20020099423 July 25, 2002 Berg et al.
20020103510 August 1, 2002 Bardy et al.
20020107545 August 8, 2002 Rissmann et al.
20020107546 August 8, 2002 Ostroff et al.
20020107547 August 8, 2002 Erlinger et al.
20020107548 August 8, 2002 Bardy et al.
20020107549 August 8, 2002 Bardy et al.
20020107559 August 8, 2002 Sanders et al.
20020120299 August 29, 2002 Ostroff et al.
20020173830 November 21, 2002 Starkweather et al.
20020193846 December 19, 2002 Pool et al.
20030009203 January 9, 2003 Lebel et al.
20030028082 February 6, 2003 Thompson
20030040779 February 27, 2003 Engmark et al.
20030041866 March 6, 2003 Linberg et al.
20030045805 March 6, 2003 Sheldon et al.
20030088278 May 8, 2003 Bardy et al.
20030097153 May 22, 2003 Bardy et al.
20030105497 June 5, 2003 Zhu et al.
20030114908 June 19, 2003 Flach
20030144701 July 31, 2003 Mehra et al.
20030187460 October 2, 2003 Chin et al.
20030187461 October 2, 2003 Chin
20040024435 February 5, 2004 Leckrone et al.
20040068302 April 8, 2004 Rodgers et al.
20040087938 May 6, 2004 Leckrone et al.
20040088035 May 6, 2004 Guenst et al.
20040102830 May 27, 2004 Williams
20040127959 July 1, 2004 Amundson et al.
20040133242 July 8, 2004 Chapman et al.
20040147969 July 29, 2004 Mann et al.
20040147973 July 29, 2004 Hauser
20040167558 August 26, 2004 Igo et al.
20040167587 August 26, 2004 Thompson
20040172071 September 2, 2004 Bardy et al.
20040172077 September 2, 2004 Chinchoy
20040172104 September 2, 2004 Berg et al.
20040176817 September 9, 2004 Wahlstrand et al.
20040176818 September 9, 2004 Wahlstrand et al.
20040176830 September 9, 2004 Fang
20040186529 September 23, 2004 Bardy et al.
20040204673 October 14, 2004 Flaherty
20040210292 October 21, 2004 Bardy et al.
20040210293 October 21, 2004 Bardy et al.
20040210294 October 21, 2004 Bardy et al.
20040215308 October 28, 2004 Bardy et al.
20040220624 November 4, 2004 Ritscher et al.
20040220626 November 4, 2004 Wagner
20040220639 November 4, 2004 Mulligan et al.
20040230283 November 18, 2004 Prinzen et al.
20040249431 December 9, 2004 Ransbury et al.
20040260348 December 23, 2004 Bakken et al.
20040267303 December 30, 2004 Guenst
20050061320 March 24, 2005 Lee et al.
20050070962 March 31, 2005 Echt et al.
20050102003 May 12, 2005 Grabek et al.
20050149138 July 7, 2005 Min et al.
20050165466 July 28, 2005 Morris et al.
20050182465 August 18, 2005 Ness
20050203410 September 15, 2005 Jenkins
20050283208 December 22, 2005 Von Arx et al.
20050288743 December 29, 2005 Ahn et al.
20060042830 March 2, 2006 Maghribi et al.
20060052829 March 9, 2006 Sun et al.
20060052830 March 9, 2006 Spinelli et al.
20060064135 March 23, 2006 Brockway
20060064149 March 23, 2006 Belacazar et al.
20060085039 April 20, 2006 Hastings et al.
20060085041 April 20, 2006 Hastings et al.
20060085042 April 20, 2006 Hastings et al.
20060095078 May 4, 2006 Tronnes
20060106442 May 18, 2006 Richardson et al.
20060116746 June 1, 2006 Chin
20060135999 June 22, 2006 Bodner et al.
20060136004 June 22, 2006 Cowan et al.
20060161061 July 20, 2006 Echt et al.
20060200002 September 7, 2006 Guenst
20060206151 September 14, 2006 Lu
20060212079 September 21, 2006 Routh et al.
20060241701 October 26, 2006 Markowitz et al.
20060241705 October 26, 2006 Neumann et al.
20060247672 November 2, 2006 Vidlund et al.
20060259088 November 16, 2006 Pastore et al.
20060265018 November 23, 2006 Smith et al.
20070004979 January 4, 2007 Wojciechowicz et al.
20070016098 January 18, 2007 Kim et al.
20070027508 February 1, 2007 Cowan
20070078490 April 5, 2007 Cowan et al.
20070088394 April 19, 2007 Jacobson
20070088396 April 19, 2007 Jacobson
20070088397 April 19, 2007 Jacobson
20070088398 April 19, 2007 Jacobson
20070088405 April 19, 2007 Jacobson
20070135882 June 14, 2007 Drasler et al.
20070135883 June 14, 2007 Drasler et al.
20070150037 June 28, 2007 Hastings et al.
20070150038 June 28, 2007 Hastings et al.
20070156190 July 5, 2007 Cinbis
20070219525 September 20, 2007 Gelfand et al.
20070219590 September 20, 2007 Hastings et al.
20070225545 September 27, 2007 Ferrari
20070233206 October 4, 2007 Frikart et al.
20070239244 October 11, 2007 Morgan et al.
20070255376 November 1, 2007 Michels et al.
20070276444 November 29, 2007 Gelbart et al.
20070293900 December 20, 2007 Sheldon et al.
20070293904 December 20, 2007 Gelbart et al.
20080004663 January 3, 2008 Jorgenson
20080021505 January 24, 2008 Hastings et al.
20080021519 January 24, 2008 De Geest et al.
20080021532 January 24, 2008 Kveen et al.
20080065183 March 13, 2008 Whitehurst et al.
20080065185 March 13, 2008 Worley
20080071318 March 20, 2008 Brooke et al.
20080109054 May 8, 2008 Hastings et al.
20080119911 May 22, 2008 Rosero
20080130670 June 5, 2008 Kim et al.
20080154139 June 26, 2008 Shuros et al.
20080154322 June 26, 2008 Jackson et al.
20080228234 September 18, 2008 Stancer
20080234771 September 25, 2008 Chinchoy et al.
20080243217 October 2, 2008 Wildon
20080269814 October 30, 2008 Rosero
20080269825 October 30, 2008 Chinchoy et al.
20080275518 November 6, 2008 Ghanem et al.
20080275519 November 6, 2008 Ghanem et al.
20080288039 November 20, 2008 Reddy
20080294208 November 27, 2008 Willis et al.
20080294210 November 27, 2008 Rosero
20080294229 November 27, 2008 Friedman et al.
20080306359 December 11, 2008 Zdeblick et al.
20090018599 January 15, 2009 Hastings et al.
20090024180 January 22, 2009 Kisker et al.
20090036941 February 5, 2009 Corbucci
20090048646 February 19, 2009 Katoozi et al.
20090062895 March 5, 2009 Stahmann et al.
20090082827 March 26, 2009 Kveen et al.
20090082828 March 26, 2009 Ostroff
20090088813 April 2, 2009 Brockway et al.
20090131907 May 21, 2009 Chin et al.
20090135886 May 28, 2009 Robertson et al.
20090143835 June 4, 2009 Pastore et al.
20090171408 July 2, 2009 Solem
20090171414 July 2, 2009 Kelly et al.
20090204163 August 13, 2009 Shuros et al.
20090204170 August 13, 2009 Hastings et al.
20090210024 August 20, 2009 M
20090216292 August 27, 2009 Pless et al.
20090234407 September 17, 2009 Hastings et al.
20090234411 September 17, 2009 Sambelashvili et al.
20090266573 October 29, 2009 Engmark et al.
20090275998 November 5, 2009 Bumes et al.
20090275999 November 5, 2009 Burnes et al.
20090299447 December 3, 2009 Jensen et al.
20100013668 January 21, 2010 Kantervik
20100016911 January 21, 2010 Willis et al.
20100023085 January 28, 2010 Wu et al.
20100030061 February 4, 2010 Canfield et al.
20100030327 February 4, 2010 Chatel
20100042108 February 18, 2010 Hibino
20100056871 March 4, 2010 Govari et al.
20100063375 March 11, 2010 Kassab et al.
20100063562 March 11, 2010 Cowan et al.
20100069983 March 18, 2010 Peacock, III
20100094367 April 15, 2010 Sen
20100114209 May 6, 2010 Krause et al.
20100114214 May 6, 2010 Morelli et al.
20100125281 May 20, 2010 Jacobson et al.
20100168761 July 1, 2010 Kassab et al.
20100168819 July 1, 2010 Freeberg
20100198288 August 5, 2010 Ostroff
20100198304 August 5, 2010 Wang
20100217367 August 26, 2010 Belson
20100228308 September 9, 2010 Cowan et al.
20100234906 September 16, 2010 Koh
20100234924 September 16, 2010 Willis
20100241185 September 23, 2010 Mahapatra et al.
20100249729 September 30, 2010 Morris et al.
20100286744 November 11, 2010 Echt et al.
20100298841 November 25, 2010 Prinzen et al.
20100312309 December 9, 2010 Harding
20110022113 January 27, 2011 Zdeblick et al.
20110071586 March 24, 2011 Jacobson
20110077708 March 31, 2011 Ostroff
20110112600 May 12, 2011 Cowan et al.
20110118588 May 19, 2011 Komblau et al.
20110118810 May 19, 2011 Cowan et al.
20110137187 June 9, 2011 Yang et al.
20110144720 June 16, 2011 Cowan et al.
20110152970 June 23, 2011 Jollota et al.
20110160558 June 30, 2011 Rassatt et al.
20110160565 June 30, 2011 Stubbs et al.
20110160801 June 30, 2011 Markowitz et al.
20110160806 June 30, 2011 Lyden et al.
20110166620 July 7, 2011 Cowan et al.
20110166621 July 7, 2011 Cowan et al.
20110184491 July 28, 2011 Kivi
20110190835 August 4, 2011 Brockway et al.
20110208260 August 25, 2011 Jacobson
20110218587 September 8, 2011 Jacobson
20110230734 September 22, 2011 Fain et al.
20110237967 September 29, 2011 Moore et al.
20110245890 October 6, 2011 Brisben et al.
20110251660 October 13, 2011 Griswold
20110251662 October 13, 2011 Griswold et al.
20110270099 November 3, 2011 Ruben et al.
20110270339 November 3, 2011 Murray, III et al.
20110270340 November 3, 2011 Pellegrini et al.
20110276102 November 10, 2011 Cohen
20110282423 November 17, 2011 Jacobson
20120004527 January 5, 2012 Thompson et al.
20120029323 February 2, 2012 Zhao
20120041508 February 16, 2012 Rousso et al.
20120059433 March 8, 2012 Cowan et al.
20120059436 March 8, 2012 Fontaine et al.
20120065500 March 15, 2012 Rogers et al.
20120078322 March 29, 2012 Dal Molin et al.
20120089198 April 12, 2012 Ostroff
20120093245 April 19, 2012 Makdissi et al.
20120095521 April 19, 2012 Hintz
20120095539 April 19, 2012 Khairkhahan et al.
20120101540 April 26, 2012 O'Brien et al.
20120101553 April 26, 2012 Reddy
20120109148 May 3, 2012 Bonner et al.
20120109149 May 3, 2012 Bonner et al.
20120109236 May 3, 2012 Jacobson et al.
20120109259 May 3, 2012 Bond et al.
20120116489 May 10, 2012 Khairkhahan et al.
20120150251 June 14, 2012 Giftakis et al.
20120158111 June 21, 2012 Khairkhahan et al.
20120165827 June 28, 2012 Khairkhahan et al.
20120172690 July 5, 2012 Anderson et al.
20120172891 July 5, 2012 Lee
20120172892 July 5, 2012 Grubac et al.
20120172942 July 5, 2012 Berg
20120197350 August 2, 2012 Roberts et al.
20120197373 August 2, 2012 Khairkhahan et al.
20120215285 August 23, 2012 Tahmasian et al.
20120232565 September 13, 2012 Kveen et al.
20120245665 September 27, 2012 Friedman et al.
20120277600 November 1, 2012 Greenhut
20120277606 November 1, 2012 Ellingson et al.
20120283795 November 8, 2012 Stancer et al.
20120283807 November 8, 2012 Deterre et al.
20120290025 November 15, 2012 Keimel
20120296381 November 22, 2012 Mates
20120303082 November 29, 2012 Dong et al.
20120316613 December 13, 2012 Keefe et al.
20130012151 January 10, 2013 Hankins
20130023975 January 24, 2013 Locsin
20130035748 February 7, 2013 Bonner et al.
20130041422 February 14, 2013 Jacobson
20130053908 February 28, 2013 Smith et al.
20130053915 February 28, 2013 Holmstrom et al.
20130053921 February 28, 2013 Bonner et al.
20130060298 March 7, 2013 Splett et al.
20130066169 March 14, 2013 Rys et al.
20130072770 March 21, 2013 Rao et al.
20130079798 March 28, 2013 Tran et al.
20130079861 March 28, 2013 Reinert et al.
20130085350 April 4, 2013 Schugt et al.
20130085403 April 4, 2013 Gunderson et al.
20130085550 April 4, 2013 Polefko et al.
20130096649 April 18, 2013 Martin et al.
20130103047 April 25, 2013 Steingisser et al.
20130103109 April 25, 2013 Jacobson
20130110008 May 2, 2013 Bourget et al.
20130110127 May 2, 2013 Bornzin et al.
20130110192 May 2, 2013 Tran et al.
20130110219 May 2, 2013 Bornzin et al.
20130116529 May 9, 2013 Min et al.
20130116738 May 9, 2013 Samade et al.
20130116740 May 9, 2013 Bornzin
20130116741 May 9, 2013 Bornzin et al.
20130123872 May 16, 2013 Bornzin et al.
20130123875 May 16, 2013 Varady et al.
20130131591 May 23, 2013 Berthiaume et al.
20130131693 May 23, 2013 Berthiaume et al.
20130138006 May 30, 2013 Bornzin et al.
20130150695 June 13, 2013 Biela et al.
20130150911 June 13, 2013 Perschbacher et al.
20130150912 June 13, 2013 Perschbacher et al.
20130184776 July 18, 2013 Shuros et al.
20130196703 August 1, 2013 Masoud et al.
20130197609 August 1, 2013 Moore et al.
20130231710 September 5, 2013 Jacobson
20130238072 September 12, 2013 Deterre et al.
20130238073 September 12, 2013 Makdissi et al.
20130253342 September 26, 2013 Griswold et al.
20130253343 September 26, 2013 Waldhauser et al.
20130253344 September 26, 2013 Griswold et al.
20130253345 September 26, 2013 Griswold et al.
20130253346 September 26, 2013 Griswold et al.
20130253347 September 26, 2013 Griswold et al.
20130261497 October 3, 2013 Pertijs et al.
20130265144 October 10, 2013 Banna et al.
20130268042 October 10, 2013 Hastings et al.
20130274828 October 17, 2013 Willis
20130274847 October 17, 2013 Ostroff
20130282070 October 24, 2013 Cowan et al.
20130282073 October 24, 2013 Cowan et al.
20130296727 November 7, 2013 Sullivan et al.
20130303872 November 14, 2013 Taff et al.
20130324825 December 5, 2013 Ostroff et al.
20130325081 December 5, 2013 Karst et al.
20130345770 December 26, 2013 Dianaty et al.
20140012344 January 9, 2014 Hastings et al.
20140018876 January 16, 2014 Ostroff
20140018877 January 16, 2014 Demmer et al.
20140031836 January 30, 2014 Ollivier
20140039570 February 6, 2014 Carroll et al.
20140039591 February 6, 2014 Drasler et al.
20140043146 February 13, 2014 Makdissi et al.
20140046395 February 13, 2014 Regnier et al.
20140046420 February 13, 2014 Moore et al.
20140058240 February 27, 2014 Mothilal et al.
20140058494 February 27, 2014 Ostroff et al.
20140074114 March 13, 2014 Khairkhahan et al.
20140074186 March 13, 2014 Faltys et al.
20140094891 April 3, 2014 Pare et al.
20140100627 April 10, 2014 Min
20140107723 April 17, 2014 Hou et al.
20140121719 May 1, 2014 Bonner et al.
20140121720 May 1, 2014 Bonner et al.
20140121722 May 1, 2014 Sheldon et al.
20140128935 May 8, 2014 Kumar et al.
20140135865 May 15, 2014 Hastings et al.
20140142648 May 22, 2014 Smith et al.
20140148675 May 29, 2014 Nordstrom et al.
20140148815 May 29, 2014 Wenzel et al.
20140155950 June 5, 2014 Hastings et al.
20140169162 June 19, 2014 Romano et al.
20140172060 June 19, 2014 Bornzin et al.
20140180306 June 26, 2014 Grubac et al.
20140180366 June 26, 2014 Edlund
20140207149 July 24, 2014 Hastings et al.
20140207210 July 24, 2014 Willis et al.
20140214104 July 31, 2014 Greenhut et al.
20140222098 August 7, 2014 Baru et al.
20140222109 August 7, 2014 Moulder
20140228913 August 14, 2014 Molin et al.
20140236172 August 21, 2014 Hastings et al.
20140243848 August 28, 2014 Auricchio et al.
20140255298 September 11, 2014 Cole et al.
20140257324 September 11, 2014 Fain
20140257422 September 11, 2014 Herken
20140257444 September 11, 2014 Cole et al.
20140276929 September 18, 2014 Foster et al.
20140303704 October 9, 2014 Suwito et al.
20140309706 October 16, 2014 Jacobson
20140379041 December 25, 2014 Foster
20150025612 January 22, 2015 Haasl et al.
20150039041 February 5, 2015 Smith et al.
20150051609 February 19, 2015 Schmidt et al.
20150051610 February 19, 2015 Schmidt et al.
20150051611 February 19, 2015 Schmidt et al.
20150051612 February 19, 2015 Schmidt et al.
20150051613 February 19, 2015 Schmidt et al.
20150051614 February 19, 2015 Schmidt et al.
20150051615 February 19, 2015 Schmidt et al.
20150051616 February 19, 2015 Haasl et al.
20150051682 February 19, 2015 Schmidt et al.
20150057520 February 26, 2015 Foster et al.
20150057558 February 26, 2015 Stahmann et al.
20150057721 February 26, 2015 Stahmann et al.
20150088155 March 26, 2015 Stahmann et al.
20150105836 April 16, 2015 Bonner et al.
20150157861 June 11, 2015 Aghassian
20150173655 June 25, 2015 Demmer et al.
20150190638 July 9, 2015 Smith et al.
20150196756 July 16, 2015 Stahmann et al.
20150196757 July 16, 2015 Stahmann et al.
20150196758 July 16, 2015 Stahmann et al.
20150196769 July 16, 2015 Stahmann et al.
20150217119 August 6, 2015 Nikolski et al.
20150221898 August 6, 2015 Chi et al.
20150224315 August 13, 2015 Stahmann
20150224320 August 13, 2015 Stahmann
20150258345 September 17, 2015 Smith et al.
20150290468 October 15, 2015 Zhang
20150297905 October 22, 2015 Greenhut et al.
20150297907 October 22, 2015 Zhang
20150305637 October 29, 2015 Greenhut et al.
20150305638 October 29, 2015 Zhang
20150305639 October 29, 2015 Greenhut et al.
20150305640 October 29, 2015 Reinke et al.
20150305641 October 29, 2015 Stadler et al.
20150305642 October 29, 2015 Reinke et al.
20150306374 October 29, 2015 Seifert et al.
20150306375 October 29, 2015 Marshall et al.
20150306406 October 29, 2015 Crutchfield et al.
20150306407 October 29, 2015 Crutchfield et al.
20150306408 October 29, 2015 Greenhut et al.
20150321016 November 12, 2015 O'Brien et al.
20150328459 November 19, 2015 Chin et al.
20160015322 January 21, 2016 Anderson et al.
20160023000 January 28, 2016 Cho et al.
20160030757 February 4, 2016 Jacobson
20160033177 February 4, 2016 Barot et al.
20160121127 May 5, 2016 Klimovitch et al.
20160121128 May 5, 2016 Fishler et al.
20160121129 May 5, 2016 Persson et al.
20160213919 July 28, 2016 Suwito et al.
20160213937 July 28, 2016 Reinke et al.
20160213939 July 28, 2016 Carney et al.
20160228026 August 11, 2016 Jackson
20160317825 November 3, 2016 Jacobson
20160367823 December 22, 2016 Cowan et al.
20170014629 January 19, 2017 Ghosh et al.
20170035315 February 9, 2017 Jackson
20170043173 February 16, 2017 Sharma et al.
20170043174 February 16, 2017 Greenhut et al.
Foreign Patent Documents
2008279789 October 2011 AU
2008329620 May 2014 AU
2014203793 July 2014 AU
1003904 January 1977 CA
202933393 May 2013 CN
0362611 April 1990 EP
503823 September 1992 EP
1702648 September 2006 EP
1904166 June 2011 EP
2433675 January 2013 EP
2441491 January 2013 EP
2452721 November 2013 EP
1948296 January 2014 EP
2662113 January 2014 EP
2471452 December 2014 EP
2760541 May 2016 EP
2833966 May 2016 EP
2000051373 February 2000 JP
2002502640 January 2002 JP
2004512105 April 2004 JP
2005508208 March 2005 JP
2005245215 September 2005 JP
2008540040 November 2008 JP
5199867 February 2013 JP
9500202 January 1995 WO
9636134 November 1996 WO
9724981 July 1997 WO
9826840 June 1998 WO
9939767 August 1999 WO
0234330 January 2003 WO
02098282 May 2003 WO
2005000206 April 2005 WO
2005042089 May 2005 WO
2006065394 June 2006 WO
2006086435 August 2006 WO
2006113659 October 2006 WO
2006124833 May 2007 WO
2007073435 June 2007 WO
2007075974 July 2007 WO
2009006531 January 2009 WO
2012054102 April 2012 WO
2013080038 June 2013 WO
2013098644 August 2013 WO
2013184787 December 2013 WO
2014120769 August 2014 WO
Other references
  • US 8,886,318 B2, 11/2014, Jacobson et al. (withdrawn)
  • Asirvatham et al., “Intramyocardial Pacing and Sensing for the Enhancement of Cardiac Stimulation and Sensing Specificity,” PACE, vol. 30, pp. 748-754, Jun. 2007.
  • Henz et al., “Synchronous Ventricular Pacing without Crossing the Tricuspid Valve or Entering the Coronary Sinus-Preliminary Results,” Journal of Cardiovascular Electrophysiology, vol. 20(12):1391-1397, Dec. 2009. doi: 10.1111/j.0540-8167.2009.01556.x.
  • “Instructions for Use System 1, Leadless Cardiac Pacemaker (LCP) and Delivery Catheter,” Nanostim Leadless Pacemakers, pp. 1-28, 2013.
  • Hachisuka et al., “Development and Performance Analysis of an Intra-Body Communication Device,” The 12th International Conference on Solid State Sensors, Actuators and Microsystems, vol. 4A1.3, pp. 1722-1725, 2003.
  • Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, Jan. 29, 2016, 15 pages.
  • Seyedi et al., “A Survey on Intrabody Communications for Body Area Network Application,” IEEE Transactions on Biomedical Engineering,vol. 60(8): 2067-2079, 2013.
  • Spickler et al., “Totally Self-Contained Intracardiac Pacemaker,” Journal of Electrocardiology, vol. 3(384): 324-331, 1970.
  • Wegmüller, “Intra-Body Communication for Biomedical Sensor Networks,” Diss. ETH, No. 17323, 1-173, 2007.
Patent History
Patent number: 10905886
Type: Grant
Filed: Dec 28, 2016
Date of Patent: Feb 2, 2021
Patent Publication Number: 20170182327
Assignee: CARDIAC PACEMAKERS, INC. (St. Paul, MN)
Inventor: Lili Liu (Maple Grove, MN)
Primary Examiner: Eun Hwa Kim
Application Number: 15/392,668
Classifications
Current U.S. Class: Testing Means Inserted In Body (600/486)
International Classification: A61N 1/375 (20060101); A61N 1/368 (20060101); A61B 5/042 (20060101); A61B 5/00 (20060101); A61N 1/05 (20060101); A61N 1/365 (20060101); A61N 1/372 (20060101);